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VDAC1VDAC1 is found at the crossroads of metabolic and survival pathways. VDAC1 controls metabolic cross-talk be-
tween mitochondria and the rest of the cell by allowing the inﬂux and efﬂux of metabolites, ions, nucleotides,
Ca2+ and more. The location of VDAC1 at the outer mitochondrial membrane also enables its interaction with
proteins that mediate and regulate the integration of mitochondrial functions with cellular activities. As a trans-
porter ofmetabolites, VDAC1 contributes to themetabolic phenotype of cancer cells. Indeed, this protein is over-
expressed inmany cancer types, and silencing of VDAC1 expression induces an inhibition of tumor development.
At the same time, along with regulating cellular energy production and metabolism, VDAC1 is involved in the
process of mitochondria-mediated apoptosis by mediating the release of apoptotic proteins and interacting
with anti-apoptotic proteins. The engagement of VDAC1 in the release of apoptotic proteins located in the
inter-membranal space involves VDAC1 oligomerization that mediates the release of cytochrome c and AIF to
the cytosol, subsequently leading to apoptotic cell death. Apoptosis can also be regulated by VDAC1, serving as
an anchor point for mitochondria-interacting proteins, such as hexokinase (HK), Bcl2 and Bcl-xL, some of
which are also highly expressed in many cancers. By binding to VDAC1, HK provides both a metabolic beneﬁt
and apoptosis-suppressive capacity that offer the cell a proliferative advantage and increase its resistance to che-
motherapy. Thus, these and other functions point to VDAC1 as an excellent target for impairing the re-programed
metabolism of cancer cells and their ability to evade apoptosis. Here, we review current evidence pointing to the
function of VDAC1 in cell life and death, and highlight these functions in relation to both cancer development and
therapy. In addressing the recently solved 3D structures of VDAC1, this review will point to structure–function
relationships of VDAC as critical for deciphering how this channel can perform such a variety of roles, all of
which are important for cell life and death. Finally, this review will also provide insight into VDAC function in
Ca2+ homeostasis, protection against oxidative stress, regulation of apoptosis and involvement in several
diseases, as well as its role in the action of different drugs. We will discuss the use of VDAC1-based strategies
to attack the alteredmetabolism and apoptosis of cancer cells. These strategies include speciﬁc siRNA able to im-
pair energy and metabolic homeostasis, leading to arrested cancer cell growth and tumor development, as well
VDAC1-basedpeptides that interactwith anti-apoptotic proteins to induce apoptosis, thereby overcoming the re-
sistance of cancer cell to chemotherapy. Finally, small molecules targeting VDAC1 can induce apoptosis. VDAC1
can thus be considered as standing at the crossroads betweenmitochondrial metabolite transport and apoptosis
and hence represents an emerging cancer drug target. This article is part of a Special Issue entitled: Membrane
channels and transporters in cancers.
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The impression of a ‘leaky’ outer mitochondrial membrane (OMM),
attributed to an unknown membrane structural property, led scientists
to focus on transmembrane proteins embedded in the inner membrane
as being responsible [1]. During the period spanning 1976–1984, using
electrophysiology and electron microscopy [1], it was unambiguously
demonstrated that OMM leak was due to unique anion-selective chan-
nels, leading to the identiﬁcation of voltage-dependent anion channels,
or in short, VDACs. The last three decades have seen substantial devel-
opment in our understanding of VDAC1 structure and function [2,3].
From being channels considered as ‘anionic molecules large enough to
feel the distribution of electrical potential’ [1], we now know that
VDACs transport cations, such as Ca2+, as well as many charged and
non-charged metabolites, with selectivity for cations and anions being
modiﬁed bymembrane voltage [1]. Moreover, VDACmediatesmetabol-
ic cross-talk between the mitochondria and the rest of the cell [2,4,5].
Accumulating evidence also points to VDAC as being a key player in
the regulation of mitochondria-mediated apoptosis and implicated in
cancer and neurodegenerative disorders [2,4–6]. Thus, it is now recog-
nized that VDAC not only plays a crucial role in regulating themetabolic
and energetic functions of mitochondria but is also a key player in
mitochondria-mediated apoptosis. As such, VDAC appears to be a
convergence point for a variety of cell survival and cell death signals.
Accordingly, several recent reviews have focused on VDAC as being an
essential player in apoptosis [2,7], on novel VDAC functions [8], onVDAC structure and function [9,10], on the location and function of
VDAC in the sarcoplasmic reticulummembrane [11], and on the modu-
lation of VDAC and its contribution to the roles played by mitochondria
in cell life and death [12–14], as well as on the role of VDAC in cancer
[5,6], in hypoxia [15] and in the Warburg effect [16–18].
The present review outlines current knowledge related to VDAC1 as
a multi-functional mitochondrial protein regulating cell life and death
and its importance for cancer cell survival. Speciﬁcally, we highlight re-
cent results related to the modulation of VDAC1 activities by associated
proteins and suggest a novel mechanism for VDAC1-mediated release
of apoptotic proteins and regulation of apoptosis. We also consider
the over-expression of VDAC1 in various cancer types and possible
VDAC1-based cancer therapeutic applications.
2. VDAC isoforms, structure and channel activity
VDAC is a 31 kDa pore-forming protein found in the OMM of all
eukaryotes [19], where it functions as gatekeeper for the entry and
exit of mitochondrial metabolites, thereby controlling cross-talk
between mitochondria and the rest of the cell.
2.1. VDAC
In mammals, three versions of VDAC have been identiﬁed, VDAC1,
VDAC2 and VDAC3 [20]. The three proteins have similar molecular
weights (30–35 kDa), share approximately 70% identity and show
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functions [2,21–23]. The three isoforms are nearly ubiquitous in all tissue
types, with VDAC2 and VDAC3 expression levels being lower by one and
two orders of magnitude than that of VDAC1 [2,21]. Human (h)VDAC-2
is, however, abundant in the sperm ﬂagellum [24]. Our current
information on VDAC primarily stems from extensive studies of VDAC1
[2,5,6,10–13]. VDAC3 was also found to be associated with the centriole
and to modulate its assembly via interaction with Mps1 [25,26].
The three isoforms share several structural and functional similari-
ties yet signiﬁcant differences exist between them in terms of function-
ality [22,27–29]. Recombinant VDAC1 and VDAC2 demonstrated
channel activity upon reconstitution into a lipid bilayer (PLB) [30].
Recently, hVDAC3 was also reconstituted into PLB and showed only
slightly voltage-dependent conductance [31].
While the presence of all three isoforms is not essential for cell
survival, it was observed that VDAC2−/− mice (but not those lacking
VDAC1) died in the embryonic stage and could not be rescued by
over-expression of VDAC1 [2,4,5]. hVDAC-2 expression is associated
with neurodegerative diseases, including amylotropic lateral sclerosis
(ALS) [32], hypoxia [33], epilepsy [34] and Alzheimer's disease [4,35],
and serves amajor role in determining apoptosis rates in disease, partic-
ularly cancer [2,36]. The absence of VDAC1 causes multiple defects in
respiratory complex activities of the heart and gastrocnemius, a mixed
glycolytic/oxidativemuscle. VDAC3−/−mice develop defects in respira-
tory complex IV activity only in the heart muscle [37]. Other functional
differences between the VDAC isoforms with respect to apoptosis are
presented below.
VDAC1, thought to be located exclusively in the OMM, has also been
localized to cell compartments other than mitochondria based on im-
munoﬂuorescence, ﬂow cytometry and EM immunogold labeling [38].
These alternate compartments include the plasmamembrane of various
cells [38], the sarcoplasmic reticulum of skeletal muscles [39], the endo-
plasmic reticulum (ER) of rat cerebellum [40], and in caveolae and
caveolae-like domains. Accordingly, plasma membrane localized VDAC
was proposed and termed plasmalemal (pl)-VDAC1. This version of
the channel is thought to contain an N-terminal signal peptide respon-
sible for targeting to the cell membrane [41]. While some studies have
detected VDAC on the plasma membrane, this form of the protein
remains a matter of dispute [42]. Still, several functions for the pl-
VDAC1 have been proposed, including serving as part of the outwardly
rectifying depolarization-induced chloride channel complex [43], being
involved in brain tissue volume regulation [44], and contributing to ATP
release and cell volume regulation [45].
2.2. VDAC1 structure
In 2008, the three-dimensional structure of VDAC isoform 1 was
determined at atomic resolution by three independent approaches
[46–48]. The structure of hVDAC1 (283 amino acids) was solved in
parallel by nuclear magnetic resonance spectroscopy (NMR) [47] and
by a novel approach combining nuclearmagnetic resonance spectrosco-
py and X-ray crystallography [46]. The three-dimensional structure of
VDAC1 from mouse (mVDAC1) was determined by X-ray crystallogra-
phy [48]. Mouse VDAC1 differs from human VDAC1 by just four amino
acid substitutions, namely threonine 55 to asparagine, methionine 129
to valine, alanine 160 to serine and isoleucine 227 to valine. The three
structures are almost identical, featuring a 19-stranded β-barrel and
an N-terminal α-helical located horizontally midway within the pore
(Fig. 1). Unlike other known transmembrane β-barrels, VDAC1 includes
an odd number of strands, a consequence of which is that barrel closure
is achieved by parallel hydrogen bonding between strands 1 and 19,
creating a weak point in the barrel structure [10,46]. Additionally, the
N-terminal helix is required to preserve a cylindrical barrel structure
in hVDAC1 [49]. Other studies contributed to further understanding of
VDAC1 structure and identiﬁcation of amino acid residues important
for the structure and/or function of the protein [50–53].In contrast to VDAC1, structural characterization of VDAC2 and 3 is
rather limited. Recently, the structure of zebraﬁsh VDAC2 was resolved
at 2.8 Å resolution, revealing a dimer [54]. This assessment was con-
ﬁrmed in solution by double electron–electron resonance spectroscopy
and by cross-linking experiments.
A wide range of biochemical and biophysical studies have addressed
the structural arrangement of the N-terminal 25 residues of VDAC1, as
well as the functional roles assumed by this domain. Previous studies
suggest that the N-terminal domain of VDAC1 can be exposed to the cy-
toplasm [8], crosses themembrane [55] or lies on themembrane surface
[43]. On the other hand, the three solved 3D VDAC1 structures suggest
that the N-terminal region of VDAC1 is located inside the pore and
that a helical conformation is present within the N-terminal region,
which is attached to the channel wall but is not a part of it [46–48].
The N-terminal region interacts with the β-barrel wall and is stabilized
by several hydrogen bonds [48]. The position of the N-terminal region
α-helix (comprising residues Tyr-7 to Val-17) within the barrel is
approximately at the midpoint of the channel well [46]. Similar posi-
tioning was seen in the crystal structure of mouse VDAC1, with the he-
lical region formed by amino acids 6–20 but being broken into two
segments at Leu-10-Gly-11. Residues 11–20 were difﬁcult to observe
by solution-state NMR, suggesting the dynamic behavior of this seg-
ment [47]. A breaking of the helix at glycine 11 could increase mobility
in this region. Another important VDAC1 structural element is the
stretch of multiple glycine residues (21GlyTyrGlyPheGly25) present in
the sequence [1,5] that connects the N-terminal domain to β-strand 1
of the barrel and that is highly conserved among mammals [56]. It
was proposed that this glycine-rich sequence provides the ﬂexibility
required for N-terminal region translocation out of the internal pore of
the channel [49]. The GlyTyrGlyPheGly motif is conserved in mammali-
an VDAC1 and Caenorhabditis elegans but not in yeast.
Accumulating evidence suggests that the N-terminal region of
VDAC1 constitutes a mobile component of the channel. In recent stud-
ies, the location of the N-terminal domain of VDAC1 within the pore
and its translocation were demonstrated using site-directedmutagene-
sis and cysteine substitution, in combination with a thiol-speciﬁc cross-
linker [49]. It was further demonstrated that the N-terminal region of
VDAC1 exists in a dynamic equilibrium, either located within the pore
or freely exposed to the cytosolic face of the β-barrel. Further evidence
suggesting that theN-terminal region of VDAC1 in fact constitutes amo-
bile component of the protein comes from the observations showing
that (a) this protein segment exhibits motion during voltage gating
[57–59], (b) anti-VDAC1 antibodies raised against the N-terminal re-
gion of the protein interact with membranal VDAC1 [12,60,61], and
(c) this section mediates the interaction of VDAC1 with the anti-
apoptotic and pro-survival factors, hexokinase (HK)-I, HK-II and Bcl2,
suggesting its exposure out of the pore [49,62].
Several different functional roles for this domain have also been
proposed. It was proposed that it forms a segment of the channel wall,
acting as the voltage sensor [58], this supported by the ﬁndings that
N-terminal-truncated murine VDAC1 showed no voltage dependence
yet exhibited high conductance at all membrane potentials tested [58,
59,62]. In addition, several mutations in the α-helix (at the conserved
Asp-16 and Lys-20 positions) affected the voltage-sensing mechanism
of yeast VDAC [63]. The N-terminal segment was further proposed to
regulate the conductance of ions and metabolites passing through the
VDAC1 pore [48]. Finally, the N-terminal domainwas proposed to regu-
late cytochrome c (Cyto c) release and subsequent apoptosis [49,62]
(see Section 4.6).
2.3. VDAC1 channel conductance, properties and regulation
The channel activity of VDAC can be reconstituted in a planar lipid
bilayer (PLB) (Fig. 2A). Upon addition of puriﬁed VDAC1 to one of the
compartments (termed the cis-side), VDAC1 exhibits a conductance of
~3.5–4.0 nS in 1 M KCl or NaCl, at voltages between −10 mV and
Fig. 1.Proposed three-dimensional structure of VDAC1.A, C. Side- and top-views of theX-ray crystal structure ofmouseVDAC1 [48] in a ribbon representation. Theβ-barrel is formedby 19
β-strands and the N-terminal helix, colored in pink, is folded into the pore interior. β-Strands 1 and 19 are parallel and colored green and yellow, respectively. B, D. Structure of the dimer
formed by VDAC1monomers with proposedβ-strands involved in the dimerizationmarked 1 and 19, and the residues at the interface annotated (PDB ID: 3EMN). E. VDAC1 in a proposed
conformation with the N-terminal domain outside the channel pore where it can interact with other proteins.
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VDAC1 exists in a high conductive state, with the channel being stable
in a long-lived open state. At high positive or negative potentials
(N40 mV), VDAC1 switches to lower conductance states and presents
multiple sub-states with different ionic selectivities and permeabilities
[65,66] (Fig. 2C).
VDAC channels display ion-selectivity that depends on the voltage
across the membrane [66]. In the main conductance state, VDAC1
shows a preference for transporting anions over cations [67]. VDAC1
is permeable to small ions (e.g. Cl−, K+, Na+) yet also to large anions,
such as glutamate [65] and ATP [68], and to large cations, such as
acetylcholine, dopamine [65] and Tris [69]. The closed state remains
permeable to small ions but not to larger molecules like ATP and
ADP [68].
The involvement of the N-terminal region of VDAC1, a 25 residue-
long sequence containing an α-helical moiety in the voltage gating of
the channel has been demonstrated in various studies [49,58,59,62,63,
70]. A wide range of predictions has been made as to the functional
disposition of this domain, ranging from it forming a segment of the
channel wall, to acting as the voltage sensor, and to regulating the
conductance of ions and metabolites passing through the VDAC pore
[58,67]. Indeed, voltage dependence of conductance was not observed
with N-terminal-truncated Δ(26)mVDAC1 that exhibited high conduc-
tance at all tested voltages [62,71]. In addition, several mutations in the
α-helix (the conserved Asp-16 and Lys-20) residues and in β-strands
β1-β5 (Lys46, Lys61, Lys65 and Lys84) affect the voltage-sensing
mechanism of Saccharomyces cerevisiae VDAC (scVDAC) [63].Thus, it seems that theN-terminal domain of VDAC1 functions in the
regulation of the electrophysiological features of the channel and ion
ﬂuxes.
3. VDAC1 as a multi-substrate transporter
The role of VDAC1 in cellular metabolism is crucial, where it serves
as the main interface between mitochondrial and cellular metabolisms.
The functions of VDAC1 in metabolism and energy homeostasis are
reﬂected by its facilitation of the transport of ions, nucleotides and
other metabolites up to 5 kDa across the OMM [2,9,55] (Fig. 3A).
3.1. VDAC1 as a cellular metabolite transporter
VDAC1 allows two-way trafﬁc, mediating the entry ofmetabolites in-
cluding pyruvate, malate, succinate, and NADH into mitochondria and
the exit of newly formed molecules, such as hemes, from mitochondria
[2]. In the open state, VDAC1 allows free shuttling of ATP and ADP.
Mitochondria-generated ATP is transported to the cytosol for exchange
with ADP, which is utilized for ATP generation via oxidative phosphory-
lation (Fig. 3A). The importance of VDAC1 in cell energy andmetabolism
homeostasis is reﬂected in the ﬁndings that down-regulation of VDAC1
expression resulted in reducedmetabolite exchange betweenmitochon-
dria and the cytosol and inhibited cell growth, showing VDAC1 as essen-
tial for energy production and cell growth [60]. In the same way,
mitochondrial function is connected to VDAC1 closure, which limits the
normal ﬂow of metabolites in and out of mitochondria [72,73].
Fig. 2. Schematic presentation depicting the planar lipid bilayer reconstitution assay systemused to study channel conductance properties. A. VDAC channel activity ismeasured following
its reconstitution into a PLB and measuring the current passing through the channel when a salt concentration gradient or voltage is applied across the bilayer. The membrane serves as a
capacitor, while the ions carry the current. The cis side is deﬁned as the compartment to which VDAC was added. Currents were recorded under voltage-clamp using a Bilayer Clamp
BC-535B ampliﬁer (Warner Instruments, Hamden, CT). Currents were measured with respect to the trans side of the membrane (ground). The currents were low-pass-ﬁltered at 1 kHz,
and digitized on-line using a Digidata 1440-interface board and pCLAMP 10.2 software (Axon Instruments, Union City, CA). B. Coomassie blue-stained puriﬁed VDAC1 was isolated from
rat liver mitochondria as described previously [430]. C. A typical recording of the activity of puriﬁed VDAC1 incorporated into a PLB is presented as current traces obtained in symmetric
solution (1 M NaCl) in response to voltage steps from 0 mV to either−10 or−60 mV. When the voltage was changed from 0 to−10 mV, the channel conductance remained constant
with time. However, when the voltagewas changed from 0 to−60mV, the current ﬁrst increased, due to a greater driving force but within less than 1 s the channel conductance decreased.
The dashed lines indicate the zero current level (0), the sub-state (s) of the channel and the maximal current (m). D. Multi-channel recordings of the average steady-state conductance of
VDAC1 are presented as a function of voltage. The conductance at a given voltage was normalized to the conductance at 10 mV. This voltage-dependent behavior is well known for VDAC1.
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to kinases has been presented in several studies. Found in the OMM,
VDAC1 is able to interactwith proteins thatmediate and regulate the in-
tegration of mitochondrial functions with other cellular activities.
VDAC1 interacts with HK and creatine kinase (CrK) to convert newly
generated ATP into high-energy storage forms, like glucose-6-
phosphate (G-6-P) and creatine phosphate in brain andmuscle, respec-
tively. It was proposed that at the contact sites between the inner and
outer mitochondrial membranes, VDAC1 forms a complex with
ADP/ATP carrier, the adeninenucleotide translocase (ANT), and creatine
kinase [74]. The interaction of VDAC1 with hexokinase (HK) allows for
coupling between oxidative phosphorylation and glycolysis (see
Section 8.1). Regulation of VDAC1 permeability to ATP by dimeric
αβ-tubulin was proposed, with αβ-tubulin thought to block VDAC1
conductance, leading to the channel becoming impermeable to ATP
[75]. The over-expression of VDAC1 in some cancer cells may be related
to its multiple activities, especially those required by high energy-
demanding cancer cells [6].
3.2. VDAC1 in cholesterol and lipid transport
Cholesterogenesis, the biological synthesis of cholesterol, is greatly
elevated in various cancer cells, and especially in hepatocellular
carcinoma (hepatoma) cells [76]. In general, cancer cells exhibit a
2–10-fold increase in mitochondrial cholesterol, in comparison to livermitochondria [77]. This high level of cholesterogenesis results in abnor-
mally elevated mitochondrial cholesterol levels, with the increase oc-
curring in the OMM [78,79]. For instance, the OMM fraction of Ehrlich
or AS30-D tumor cell mitochondria was found to contain 3.5–5 times
more free cholesterol than did the OMM from rat liver mitochondria,
while a less than 2-fold increase in cholesterol was noted in the IMM
[77]. High membrane cholesterol has been shown to alter the ﬂuidity
of biological membranes [80] and consequently is detrimental to the
function of mitochondria in hepatocellular carcinoma cells [81] and
other cell types [79].
Cholesterol is transported across the OMM (Fig. 3A) [82]. VDAC1 is
considered to be a necessary component of a protein complex engaged
in mitochondrial membrane cholesterol distribution and transport and
to play an important role in altered cholesterol synthesis and transport
in Morris hepatoma cells [83]. Cholesterol import into mitochondria is
mediated by a hormone-induced 140–200 kDa multi-protein complex
called the transduceosome, which is composed of cytosolic and OMM
proteins that control the rate of cholesterol entry into the OMM
[84,85]. This complex includes the OMM high-afﬁnity cholesterol-
binding protein translocator protein (TSPO), the steroidogenic acute
regulatory protein (STAR), and VDAC1 [86–88]. TSPO interacts with
VDAC1, helping to anchor the multi-protein complex to the OMM and
assisting with the binding and import of STAR [87], and thus serves as
a regulator of steroidogenesis [89]. The interaction of phosphorylated
STAR with VDAC1 facilitates the processing of the 37 kDa phospho-
Fig. 3. Schematic representation of VDAC1 as a multi-functional channel involved in cell survival and cell death. A. VDAC1 functions in cell life— The various functions of VDAC1 include
control of themetabolic cross-talk between themitochondria and the rest of the cell, cellular energy production by transporting ATP/ADP and NADH between the inter-membrane space
and the cytosol and by binding HK, Ca2+ signaling by transporting Ca2+, and cholesterol transport. Also presented are the Ca2+ inﬂux and efﬂux transport systems in the outer and inner
mitochondrial membranes and Ca2+-mediated regulation of the TCA cycle. The activation of pyruvate dehydrogenase (PDH), isocitrate dehydrogenase (ICDH) and α-ketoglutarate
dehydrogenase (α KGDH) by intra-mitochondrial Ca2+, leading to enhanced activity of the TCA cycle, is shown. The electron transport chain (ETC) and the ATP synthase (FoF1) are also pre-
sented. VDAC1 in the OMM is presented as a Ca2+ channel. In the IMM, the uptake of Ca2+ into the matrix is mediated by a Ca2+-selective transporter, the mitochondrial Ca2+ uniporter
(MCU), regulated by a calcium-sensing accessory subunit (MICU1). Ca2+ efﬂux is mediated by NCLX, a Na+/Ca2+ exchanger. High levels of matrix Ca2+ accumulation trigger the opening
of the PTP, a fast Ca2+ release channel. VDAC1 function in transport of H2O2 is also presented. Molecular ﬂuxes are indicated by arrows. B. VDAC1 function in cell death— Different models
for the release of apoptogenic proteins, such as Cyto c (purple) and AIF (yellow), from the mitochondrial inter-membrane space to the cytosol, leading to apoptosis. These models include:
(a) VDAC1 closure and OMM rupture serves as the cytochrome c release pathway— Prolonged VDAC closure leads to mitochondrial matrix swelling and OMM rupture, resulting in the appear-
ance of a non-speciﬁc release pathway for apoptogenic proteins; (b) a permeability transition pore (PTP) provides the apoptogenic proteins release pathway—A large conductance pore-forming
complex, the PTP, composed of VDAC at the OMM, ANT at the IMM and Cyp D in the matrix, allows apoptogenic protein release; (c) Bax activation, followed by its oligomerization, results in
OMM permeabilization— Upon apoptosis induction, Bax becomes associated with mitochondria as a large oligomer/complex forming a Cyto c-conducting channel in the OMM; (d) a pore is
formed by oligomerized forms of Bax and Bak— Bax/Bak oligomerization, proposedly activated by BH3-only proteins (e.g. Bid), result in OMM permeabilization and Cyto c release; (e) a Bax-
and VDAC1-based hetro-oligomermediates cytochrome c release— The interaction of pro-apoptotic proteins (Bax/Bak)with VDAC forms a cytochrome c release pathway; (f)MAC as the release
pathway —MAC, proposed to comprise Bax and/or Bak, offers a high-conductance channel and a putative cytochrome c release channel; (g) oligomeric VDAC1 as a channel for the release
of apoptotic proteins — A protein-conducting channel is formed within a VDAC1 homo-oligomer, allowing Cyto c release and apoptotic cell death; (h) mitochondrial Ca2+ overload induces
apoptosis—Upon Ca2+ overload in thematrix, Ca2+ transportmediated by VDAC1 across theOMMand by theMCU in the IMM lead to dissipation of themembrane potential, mitochondria
swelling, PTP opening, Cyto c release and apoptotic cell death. PTP opening is also accompanying by an efﬂux of the accumulated Ca2+ into the cytosol.
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adaptor proteins was shown to contain binding motifs for important
functional sites in STAR, TSPO, and VDAC1 [90] (Fig. 3A).Thedisruption of cholesterolwas deemed responsible for the release
of VDAC frommembranes in extraction experiments [91,92]. High cho-
lesterol can reduce the activity of membrane-associated proteins and
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that the increased content of cholesterol in the mitochondria of cancer
cells could impact the binding of HK to VDAC1 [77,93]. Conversely, the
increased binding of HK to the mitochondria of cancer cells may play a
role in mediating increased synthesis and uptake of cholesterol into
the mitochondria of cancer cells [93]. Recently, it has been proposed
that a glycine motif (GxxxG) in the N-terminal part of VDAC1, localized
between positions 20–24, is responsible for cholesterol binding [94].
The above ﬁndings thus point to VDAC1 as affecting cholesterol syn-
thesis and transport, as well as being subject to cholesterol-mediated
regulation. This may carry implications for various mitochondrial
activities, including oxidative phosphorylation and apoptosis induction,
as well as for the propensity of cancer cells to exhibit a glycolytic
phenotype.
Finally, it appears that VDAC1 is involved not only in cholesterol
transport across the OMM but could also be part of a complex allowing
the transport of fatty acids through the OMM in rat liver mitochondria
[95]. It is postulated that VDAC acts as an anchor, linking the long-
chain acyl-CoA synthetase (ACSL) from the outer surface of the OMM
and carnitine palmitoyltransferase 1a (CPT1a), which faces the inter-
membrane space. In the proposed model, upon activation by ACSL,
acyl-CoAs are transferred across the OMM by VDAC1 to the intermem-
brane space where they are converted by CPT1a into acylcarnitine.
Furthermore, it was recently proposed that VDAC behaves as a lipid
sensor [96].
3.3. VDAC1 as a Ca2+ transporter
As a ubiquitous cellular signal, Ca2+ not only stimulates a number of
intercellular events but also triggers cell death pathways, including ap-
optosis, upon changes in its intracellular concentration. Ca2+ signals
regulate Ca2+-dependent enzymes, such as phospholipases, proteases,
and nucleases, all of which are important during injury or cell death
[97] (Fig. 3A). In addition to their metabolic and apoptotic roles, mito-
chondria also serve as amajor hub of cellular Ca2+ homeostasis. Indeed,
mitochondrial Ca2+ homeostasis is fundamental for awide range of cel-
lular activities, such as control of oxidative phosphorylation [98,99],
modulation of cytosolic calcium signals [100], cell death [101], secretion
[102,103] and reactive oxygen species (ROS) production in cancerous
cells [104]. Intra-mitochondrial Ca2+ controls energy metabolism by
enhancing the rate of NADHproduction bymodulating critical enzymes,
such as those of the tricarboxylic acid (TCA) cycle and fatty acid
oxidation [105,106], linking glycolysis to the TCA cycle [107] (Fig. 3A).
Ca2+ transport across the IMM is mediated via several recently
identiﬁed proteins. The mitochondrial Ca2+ uniporter (MCU) has been
identiﬁed [108,109], as has its regulatory protein, the EF hand-
containing protein termed MICU1 (mitochondrial calcium uptake
1) that acts as a Ca2+ sensor controlling mitochondrial Ca2+ entry
mediated by MCU [110]. The mitochondrial inner membrane protein
associated with the control of mitochondrial volume homeostasis,
Letm1 (leucine zipper-EF hand-containing transmembrane 1) was
also proposed to act as a Ca2+/H+ antiporter [111,112], to be essential
for normal glucose metabolism and to alter brain function in
Wolf–Hirschhorn syndrome [113]. The function of this protein in Ca2+
homeostasis has been discussed recently [114]. Efﬂux of Ca2+ from
the mitochondrial matrix is mediated by the Na+/Ca2+ exchanger su-
perfamily, with NCLX being the major Ca2+ efﬂux mediator [115,116]
(Fig. 3A). Ca2+ transport into the mitochondria is also involved in
apoptotic cell death, with Ca2+ overload triggering Cyto c release and
subsequent cell death (Fig. 3B) (see Section 4.3).
All of the mitochondrial Ca2+ transporters are located in the IMM.
Thus, to reach these transporters, Ca2+ must ﬁrst traverse the OMM.
The only identiﬁed protein mediating Ca2+ transport in the OMM is
VDAC1. Indeed, VDAC1 is highly Ca2+-permeable and modulates Ca2+
access to the mitochondrial inter-membrane space [117–119]. Indeed,
it has been shown that control of OMM Ca2+ permeability is mediatedby VDAC1 [118,120]. In another study, VDAC showed higher permeabil-
ity to Ca2+ in the closed state, rather than in the open state [119].
Several lines of evidence suggest that VDAC1 possesses divalent
cation-binding site(s): (1) La3+ and Tb3+, which are known to bind to
Ca2+-binding proteins, induce channel closure when added to VDAC
reconstituted into a PLB [117–119], (2) ruthenium red (RuR) [117,
121] and ruthenium amine binuclear complex (Ru360) [122], known
to speciﬁcally interact with several Ca2+-binding proteins [117–119],
as well as a photo-reactive analogue, azido ruthenium (AzRu) [123], in-
duce VDAC1 channel closure in a time-dependent manner and stabilize
the channel in a closed state, thus prevented permeability transition
pore (PTP) opening, (3) VDAC activity is modulated by physiological
cytosolic Ca2+ concentrations [120], and ﬁnally (4) RuR and Ru360
are unable to protect against apoptotic cell death in cells expressing
E72Q-VDAC1 [121].
Recent studies have proposed a novel physiological mechanism
whereby the magnitude of Ca2+ transfer into the mitochondrial matrix
is regulated by protein/protein interactions between Bcl-xL and VDAC
isoforms 1 and 3, with this interaction promotingmatrix Ca2+ accumu-
lation by increasing Ca2+ transfer across the OMM [124]. VDAC1
functions in cellular Ca2+ homeostasis are further reﬂected in recent
studies connecting VDAC1 to the Ca2+ cross-talk that exists between
mitochondria and the endoplasmic reticulum (ER) (see Section 6).
3.4. VDAC1 as a ROS transporter
Reactive oxygen species (ROS) arewell known as contributing to cell
proliferation and cell death [125–128]. Speciﬁcally, cellular levels of ROS
are linked to anti-tumor immunity, the oxidative tumor microenviron-
ment, and the proliferation and death of cancer cells [129]. Increased
oxidant concentrations lead to cellular transformation promoting
tumorgenicity through signaling, yet can also cause damage to DNA,
proteins, and lipids. Indeed, promoting oxidative stress selectively kills
several cancer cell lines [130–132].
Cells possess several anti-oxidant defense mechanisms, including
up-regulation of various endogenous molecules, such as glutathione,
to protect DNA from oxidative damage [133–137], or catalytic removal
of reactive species by enzymes like superoxide dismutase (SOD),
catalase, andperoxidase [138]. Oxidative stress resultswhenproduction
of ROS exceeds the capacity of mitochondrial and cellular antioxidant
defenses to remove these toxic species. Hypoxia, a characteristic of
most solid tumor microenvironments, causes a progressive elevation
in mitochondrial ROS production (chronic ROS). Prolonged hypoxia
stimulatesmultiple cell types and induces the hypoxia-inducible factors
(HIFs) thatmediate transcription of a large number of hypoxia-sensitive
genes that promote glycolysis, angiogenesis, and erythropoiesis and
hence, cellular hypoxic adaptation [139]. It is becoming clear that
hypoxia enables cells with persistent levels of elevated ROS to survive.
Themajor site of ROS production in cells is themitochondria as a re-
sult of respiratory chain reactions, in the form of by-products. In human
mitochondria, 1–2% of the consumed oxygen is converted to ROS, such
as superoxide anions (O2−•), H2O2, and hydroxyl radicals [140]. The mi-
tochondrial enzymes MnSOD and Cu/ZnSOD act to cope with the ROS
produced [135,141]. However, about 1% of the ROS escapes elimination
andwhen released to the cytosol can attack andmodify DNA, lipids and
proteins, thus affecting cell survival [142]. ROS can damage the mito-
chondrial as well as the nuclear genome, leading to direct and indirect
changes in the cell microenvironment and the triggering of tumorigen-
esis [143–146]. This requires ROS release from the mitochondria to the
cytosol. It has been proposed that the release of ROS may be mediated
by mPTP with higher ROS levels, longer mPTP openings and inner
membrane anion channel (IMAC) [147].
Yet, the underlying mechanisms of ROS transport via the OMM and
the control of this process are not clear. VDAC1 in the OMMmay serve
as the major gateway for molecules exiting the intermembrane (IMS)
space. Indeed, VDAC1 has been proposed to mediate ROS release from
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ticipation of VDAC1 in ROS transport from the IMS to the cytosol. HK-I
and HK-II bound to VDAC1 decreased ROS release from mitochondria
when over-expressed in HEK cells [149], thereby reducing intracellular
levels of ROS [150,151]. Also, expression of HK-I or HK-II was found to
protect against oxidant-induced cell death [150,152]. Thus, detachment
of HK fromVDAC1 could lead to increased ROSgeneration and release to
the cytoplasm, subsequently activating cell death. Closure of VDAC1
appeared to impede the efﬂux of superoxide anions from the IMS,
resulting in an increased steady-state level of O2−•, causing internal ox-
idative stress and sensitizing mitochondria toward Ca2+-induced MPT
[153]. Finally, the VDAC inhibitors, 4,4′-diisothiocyanatostilbene-2,2′-
disulfonic acid (DIDS) and dextran sulfate, inhibited O2−• release from
themitochondria to the cytosol [148]. As ROS induces VDAC1 oligomer-
ization (see Section 4.4), leading to the formation of a large pore that al-
lows for passage of Cyto c, the same channel could also serve as ROS
efﬂux channel. Indeed, both VDAC1 oligomerization and ROS release
are inhibited by DIDS [148,154,155].
ROS promotes Cyto c release frommitochondria [156,157]. In fact, it
has been shown that apoptosis-inducing agents, such as inorganic arse-
nic compounds [158,159] and doxorubicin [160,161], induce apoptosis
by inducing ROS generation. The inhibition of O2−•-induced apoptosis
by DIDS, an inhibitor of VDAC channel activity, or anti-VDAC1 antibod-
ies [39,162,163], suggests that O2−• induces Cyto c release via VDAC1-
dependent permeabilization of the OMM [162]. Moreover, O2−• was
found to evoke Cyto c release in VDAC1-reconstituted liposomes [162].
In other studies, it was found that ROS-induced alterations of VDAC1
and/or ANT could induceMMP selective for Cyto c release,without caus-
ing further mitochondrial damage [162,164]. Moreover, it was shown
that ROS-induced up-regulation of VDAC1 can be prevented by the
ROS chelator, epigallocatechin [165]. It has been suggested that ROS-
mediated Cyto c and SOD1 released from mitochondria involve VDAC,
leading to increased susceptibility of mitochondria to oxidative stress
and apoptosis [166].
As discussed above, themultiple functions of VDAC1 in transporting
metabolites, nucleotides, cholesterol and ROSmake VDAC1 not only the
gatekeeper of mitochondria, regulating cell life and death, but also a
critical factor for cancer cell survival.
4. Mitochondria and apoptosis
4.1. Apoptosis pathways
Apoptosis can be initiated by two signaling cascades, termed the
extrinsic and intrinsic pathways. The classical extrinsic pathway is trig-
gered by the binding of extracellular signals, like tumor necrosis factor
(TNF), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
and apoptosis antigen-1 (Fas) ligand (FASL), to death receptors, such as
tumor necrosis factor receptor 1 (TNFR1) and FAS [167]. Such interaction
leads to the recruiting of an adaptor protein and the initiating protein
procaspase 8 to the cytoplasmic domain of the death receptor. This com-
plex, the death-inducing signaling complex (DISC), activates procaspase
8 by auto-proteolysis, transforming it into mature caspase 8 [168].
Caspase 8 then activates caspases 3, 7 and 6, promoting apoptosis, with
accompanying increases in proteolysis and DNA degradation.
The intrinsic pathway can be triggered by intracellular stress signals,
such as oxidative stress and DNA damage, as well as by various
compounds acting as chemotherapeutic drugs. The intrinsic pathway
is activated when the diverse signals are sensed by mitochondria
through pro-apoptotic signals that overcome anti-apoptotic signals,
leading to mitochondria permeabilization and release of intermem-
brane apoptogenic proteins [169]. The released pro-apoptotic proteins
include Cyto c [170], Smac/DIABLO, AIF and HTRA2/OMI [171,172].
The Cyto c released to the cytosol interacts with the apoptotic
protease-activating factor 1 (Apaf-1), resulting in increased afﬁnity of
the complex for dATP whose binding is necessary for oligomerizationand formation of the apoptosome [173]. This complex now interacts
with the cysteine-aspartic protease pro-caspase 9 to form the
apoptosome,which activates the executioner caspases, such as caspases
3 and 7, and subsequent cell distruction [174]. This pathway is regulated
at several steps, including the release of Cyto c from themitochondria by
members of the Bcl-2 family of proteins [175], and that of caspases by
the IAP family of proteins [176]. In addition, it is proposed that release
of Cyto c from mitochondria is regulated via phosphorylation of Tyr48
in vivo [177], with mutant Tyr48Glu Cyto c being incapable of inducing
downstream caspase activation [178].
The AIF released from the mitochondria also acts as an effector of
apoptotic cell death and upon cleavage by calpains and/or cathepsins,
AIF is translocated to the nucleus, leading to chromatin condensation
[179] and DNA fragmentation [180]. Thus, released Cyto c and AIF are
key steps in apoptosis induction.
The extrinsic pathway can be connected with the intrinsic pathway
through the caspase 8-mediated cleavage of Bid into tBid (truncated
Bid). The C-terminal tBid fragment translocates into the mitochondria,
where it causes (either directly or indirectly) Cyto c release, resulting
in apoptosome formation, caspase activation and cell death [168].
Therefore, tBid links apoptotic signals initiated by death receptors to
mitochondria-mediated apoptosis. As such, mitochondria serve as
both initiators and accelerators of apoptotic signals. The proposed
mechanism for Cyto c release is presented below (see Section 4.3).
4.2. VDAC involvement in apoptosis
There are several signiﬁcantﬁndings connecting VDAC1 to apoptosis
and proposing that VDAC1 is an important player in the release of
apoptosis-inducing proteins from mitochondria to the cytosol [2,3,6–8,
12–14,181]. These include the following observations: (a) Cyto c re-
lease, cell death and Bax-VDAC1 interaction were all inhibited by anti-
VDAC1 antibodies [162,182,183]; (b) inhibition of Cyto c release and
cell death by HK were both shown to speciﬁcally rely on interaction
with native but not mutated VDAC1 [121,181,184]; (c) RuR interacts
with native but not mutated VDAC1 to prevent Cyto c release and cell
death [121,185,186]; (d) siRNA-mediated down-regulation of VDAC1
prevented cell death induced by cisplatin and strongly reduced
cisplatin-induced release of Cyto c, AIF and maturation of caspase 3
and cell death [187]. VDAC1-siRNA also attenuated endostatin-
induced apoptosis [188]; (e) over-expression of VDAC1was found to in-
duce apoptotic cell death, regardless of cell type [121,184,189–191]. It
has been shown that VDAC1 over-expression in endothelial cells en-
hanced the activation of caspase 9 and elevated the production of ROS
and endostatin-induced apoptosis [188]; (f) VDAC1was shown to be in-
volved in Cyto c release from proteoliposomes in vitro [162,192,193];
(g) VDAC1-deﬁcient mitochondria from mutant yeast did not exhibit
Bax/Bak-induced Cyto c release or Δψ loss [192,194]; (h) the BH4 do-
main of Bcl-xL was found sufﬁcient for inhibition of Cyto c release and
Δψ loss in VDAC1 proteoliposomes, as well as in HeLa cells and isolated
rat liver mitochondria [192,194,195]; and (i) VDAC1 interacted directly
with Bcl2 and Bcl-xL and protected against apoptosis in cells expressing
native but not mutated VDAC1 [196,197].
4.3. Proposed pathways and mechanisms for apoptogenic factors release
from the mitochondria
Mitochondria contain an arsenal of apoptogenic factors normally
residing in the IMS, such as Cyto c, AIF, Smac/DIABLO and endonuclease
G. One of the enigmas in mitochondria-mediated apoptosis concerns
the release pathway(s) of these apoptogenic factors from the IMS to
the cytosol. Speciﬁcally, it remains unclear how these apoptotic initia-
tors cross the OMM for release into the cytosol.
All of themitochondrial components known to translocate to the cy-
toplasm following an apoptotic stimulus reside in the IMS. Therefore,
only the permeability of the OMM needs to be modiﬁed for this event.
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optotic proteins from the IMS (for reviews, see [2,5,155]). Somemodels
suggest that release exclusively involves an increase in OMM perme-
ability due to the formation of a channel large enough to allow for the
release of proteins, such as Cyto c (Fig. 3B),while others consider release
to be due to disruption of OMM integrity (Fig. 3B). Brieﬂy, the major
models include:
(i) Osmotic matrix swelling — This is a process caused by a defect in
mitochondrial ATP/ADP exchange due to VDAC1 closure, leading
to OMM rupture and non-speciﬁc release of inter-membrane
proteins into the cytosol [13,72,198] (Fig. 3Ba).
(ii) Permeability transition pore (PTP) — The PTP is a high-
conductance non-speciﬁc pore linking the inner and outer mito-
chondrialmembranes (Fig. 3Bb). Opening of the PTP, in response
to over-production of ROS or Ca2+ overload, results in free
penetration of low-molecular weight substrates into the
mitochondrialmatrix, alongwithwater, leading tomitochondria
swelling and the release of Cyto c into the cytosol [12,199–201].
The proposedmajor PTP complex components include VDAC1 at
the OMM, adenine nucleotide translocase (ANT) in the IMM, and
cyclophilin D (CypD), a resident of the matrix [12,199,202,203].
While gene knockout experiments performed in mice have con-
ﬁrmed the contribution of CypD to the PTP, data obtained with
mitochondria from cells lacking some but not all ANT isoforms
[204,205] or VDAC [206] have questioned the importance of
ANT and VDAC1 for PTP formation. Recently, it was proposed
that dimers of ATP synthase form the permeability transition
pore [207].
Irrespective of the exact nature of the protein(s) responsible for
PTP formation, this entity has been demonstrated to participate
in many cell death scenarios. PTP was proposed to serve as a
Ca2+ release channel, with its transient opening offering a fast
Ca2+ release mechanism and with its persistent opening
resulting in non-regulated release of matrix Ca2+ [208]. It was
also suggested that the PTP may play a role in necrosis, yet not
in apoptosis [203,208,209].
(iii) Bax/Bak complexes — Bax and Bak are pro-apoptotic proteins,
activity of which is inhibited by the anti-apoptotic members of
the Bcl2 protein family. Bax and Bak can, however, oligomerize
to form selective large channels sufﬁcient for Cyto c release
across the OMM [210–213] (Fig. 3Bc). Cytosolic Bax is weakly
associated with mitochondria as a monomer, whereas following
apoptosis induction, it becomes associated with mitochondria as
large oligomers and complexes of 96 kDa and 260 kDa, respec-
tively. Bcl-2 prevented Bax oligomerization and insertion into
the mitochondrial membrane [214,215]. Bak can form homo-
oligomers [216] or hetro-oligomers with Bax to form a pore
after their activation by tBid [217,218].
(iv) Bax/VDAC1 complexes — The existence of hetero-oligomers com-
posed of VDAC1 and Bax forming the Cyto c release channel was
also proposed [219,220] (Fig. 3Bd).
(v) Mitochondrial apoptosis-inducing channel (MAC) — MAC is a
supra-molecular high-conductance OMM channel that was also
proposed as providing the pathway for Cyto c release [209]
(Fig. 3Be). The electrophysiological characteristics of MAC are
very similar to those of Bax channels. Depletion of Bax signiﬁcant-
ly diminished MAC activity, suggesting that Bax is an essential
constituent of MAC in some systems. Recently, it was proposed
that Bax and/or Bak form the MAC [221]. What is clear is that
MAC activation is tightly regulated by Bcl-2 family proteins
[222].
(vi) VDAC1 oligomerization—A recently proposedmodel suggests that
VDAC1undergoes conformational changes andoligomerization in
response to apoptotic stimuli, with VDAC1 oligomers forming a
pore large enough to enable the release of Cyto c, leading to theinduction of apoptosis [5,62,154,155,181,193,223–225] (Fig. 3Bf).
In support of this model, apoptosis induction was recently shown
to be correlated with an increase in VDAC1 oligomerization
(up to 20-fold), while the apoptosis inhibitor, DIDS, prevented
staurosporine (STS)-induced VDAC1 oligomerization and apopto-
sis [154,155] (see Section 4.4).
(vii) Ca2+ overload—Non-physiological Ca2+ overload depolarizesmi-
tochondria by opening the PTP, with concomitant release of Cyto c
and other IMS proteins [226,227], leading to apoptotic and possi-
bly also necrotic cell death [208] (Fig. 3Bg). The mechanism of
Ca2+-mediated activation of Cyto c release is unclear.
Finally, it should be noted that multiple pathways and mechanisms
of Cyto c release could co-exist within a single model of cell death,
depending on the cell type and nature of the stimulus [228,229].
4.4. A VDAC1 oligomeric structure as a Cyto c release pathway
The diameter of the VDAC1 pore in its high conductance state is
about 2.6–3.0 nm, sufﬁcient to allow passage of nucleotides and small
molecules but insufﬁcient for a folded protein like Cyto c to traverse.
As such, the formation of a large channel comprising VDAC1monomers
and serving as the Cyto c release channel has been proposed [5,154,155,
193,223–225]. Substantial evidence supports the claim that VDAC1 can
exist as higher-order oligomers, namely as monomers, dimers, trimers,
tetramers, and hexamers, with the formation of higher ordered VDAC1-
containing complexes having been demonstrated [154,155,193,195,
230–233]. In several studies, it has been reported that both puriﬁed
soluble and membrane-embedded VDAC1 can assemble into dimers,
trimers and tetramers in a dynamic process [234]. The supra-
molecular organization of VDAC1 in native OMM has also been demon-
strated using atomic forcemicroscopy (AFM) [231,232]. Chemical cross-
linking experiments using both puriﬁed and membrane-embedded
VDAC1 also revealed the assembly of dimers, trimers, tetramers and
higher VDAC1 oligomers [193]. In addition, the application of symmetry
operators on the NMR-based structure of recombinant hVDAC1 [46] in-
dicated that itmay form a parallel dimer, although analysis of the crystal
packing of mouse VDAC1 revealed an anti-parallel dimer, which further
assembles into hexamers [235]. On the basis of electron microscopy-
based analysis of 2D crystallized OMM, it was noted that VDAC1 pores
are organized into ordered arrays, each bearing six monomers with
inter-channel contacts [236]. Recently it was suggested that the
particular lipid composition of the OMM, a proﬁle that changes upon
encountering apoptogenic stimuli, signiﬁcantly enhances VDAC1 oligo-
merization [237]. VDAC1 oligomerization is a dynamic process, such
that equilibrium between monomeric and oligomeric forms exists, as
shown by FRET technology [193].
It has been proposed that dynamic VDAC1 oligomerizationmediates
the formation of a large ﬂexible pore between individual subunits of
VDAC1, serving as a channel that allows Cyto c to cross the OMM
[5,154,155,181,193,223–225]. This concept gained experimental sup-
port when it was shown that apoptosis induction in cultured cells
leads to VDAC1 oligomerization [154]. Release of Cyto c via puriﬁed
VDAC1 reconstituted into liposomes in which Cyto c was encapsulated
has been demonstrated [162,193]. In response to various apoptosis
inducers, VDAC1 oligomerization can be enhanced up to 20-fold,
reﬂecting a shift in VDAC1 status from the monomeric toward the
oligomeric form (Fig. 4). Apoptosis-mediated enhancement of VDAC1
oligomerization was obtained regardless of the cell type or apoptosis
inducer used, including STS, curcumin, As2O3, etoposide, cisplatin,
selenite, TNF-α, H2O2 or UV light, all affecting mitochondria yet acting
via different mechanisms. Additionally, VDAC1 oligomerization and
apoptosis show similar concentration- and time-dependence on the
apoptosis stimulus involved.
Additional support for coupling between apoptosis induction and
VDAC1 oligomerization is presented by the inhibition of both processes
Fig. 4.Apoptosis stimuli induceVDAC1oligomerization:AproposedCyto c release channel. A. VDAC1oligomerization as induced by apoptosis inducers and revealed byEGS-based cross-linking.
HeLa cells were incubated with selenite (10 μM, 16 h), As2O3 (60 μM, 16 h) and cisplatin (30 μM, 16 h), then incubated at 30 °C with EGS (300 μM, 15 min), followed by SDS-PAGE (10 % ac-
rylamide) andWestern blotting using anti-VDAC1 antibodies. VDAC1monomers, dimers andmultimers are indicated. The asterisk represents intra-molecular cross-linkedmonomeric VDAC1.
B. Similar to A, Hela cellswere incubatedwith the indicated concentrations of selenite for 16 h and treated as previously described. C. The extent of apoptosis as a function of VDAC1 dimer level.
Apoptsis and VDAC1 oligomerization were induced in HeLa cells by selenite (0–10 μM, 16 h). Apoptotic cell death assayed using annexin V-FITC, PI staining and FACS analysis. D. Model for
VDAC1 oligomerization and its N-terminal region-mediated cytochrome c release. (a) Before apoptosis induction: Side-view across the membrane with VDAC1 in the monomeric state and
with the amphipathic α-helix N-terminal region cytoplasmically exposed [8] or positioned within the pore [46–48]. (b) Upon an apoptotic signal: VDAC1 oligomerization is enhanced and
the amphipathic α-helix N-terminal region of each VDAC1 molecule ﬂips into the hydrophobic pore formed by the β-barrels, forming a hydrophilic pore capable of conducting Cyto c release.
(c) Inhibition of apoptosis by anti-apoptotic proteins: HK [62], Bcl-xL [196] or Bcl-2 [197] interactwith theN-terminal region of VDAC1 to prevent its translocation and thus, the formation of the
hydrophilic pore, thereby inhibiting Cyto c release.
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VDAC1 oligomerization [154]. The relationship between VDAC1
oligomerization and apoptosis is further reﬂected in studies attributing
the apoptosis-inducing effect of As2O3 to induction of VDAC1 homo-
dimerization [183]. This effect was prevented by over-expression of
the anti-apoptotic protein, Bcl-xL [183]. Finally, the hepatitis E virus
ORF3 protein was found to up-regulate VDAC1 expression, with ORF3-
expressing cells showing higher levels of oligomeric VDAC1, as revealed
by chemical cross-linking [239].
The results presented above led us to propose a novel model in which
VDAC1 exists in a dynamic equilibrium between the monomeric and
oligomeric states,with apoptosis inducers shifting the equilibriumtoward
oligomers (Fig. 4D). VDAC1 oligomers form a conducting channel that
enables the release of Cyto c from themitochondria, leading to cell death.4.5. Contact sites between VDAC1 molecules in VDAC1 oligomers
The formation of VDAC1 trimers, tetramers, hexamers, and higher
oligomers [193,195,231,232] requires more than a single contact site
between VDAC1 monomers. The formation of a channel large enough
to allow passage of Cyto c (3.4 nm external diameter) [240] requires
six cylindrical VDAC1 monomers, each with an external diameter of
4.0 nm (representing the distance between the beta-carbon (Cb) of
Phe236 and the Cb of Leu100) [46–48], arranged around a central
pore 4.0 nm in diameter. The resolved 3D structure of recombinant
VDAC1 creates new opportunities for structural studies of VDAC1.
Some of the proposed structures suggest that the protein–protein sur-
face in a VDAC1 dimer involves amino acid residues in β-strands 1, 2,
18, and 19 from both VDAC1 monomers [46,235], as depicted in Fig. 1.
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strands 1 and 19) exist within VDAC1 oligomers. In fact, when VDAC1
monomers containing a single cysteine (C232 in β-strand 16) were
exposed to thiol speciﬁc cross-linker BMOE, dimers were obtained,
suggesting that C232 from each of the two VDAC1 monomers face
each other and are in close proximity (b8 A) within a dimer arrange-
ment [241]. This ﬁnding is surprising since according to recent VDAC1
topology models [46–48], C232 faces the channel pore. Our results sug-
gest that this residue can also be exposed outside the pore toward the
bilayer and undergo cross-linking. Furthermore, VDAC1 dimers were
also formed when a cysteine substitution was introduced at A231 in
β-strand 16 of ΔCys-rVDAC1, providing support for the proposal that
β-strand 16 is involved in another contact site in VDAC1 dimers [241].
4.6. The VDAC1 N-terminal domain and the release of Cyto c
The proposedVDAC1oligomeric channel comprises aβ-barrel that is
expected to be hydrophobic. It can thus be asked how positively
charged Cyto c could traverse such a pore. The ﬁnding that no apoptosis
was induced in cells expressing an N-terminal truncated form of VDAC1
shows that theN-terminal domain of VDAC is required for the release of
Cyto c and apoptotic cell death [62]. The proposed function of the
N-terminal region in apoptosis is thus based on the requirement of
this domain for apoptosis yet not being essential for VDAC1 oligomeri-
zation [62]. Structural studies place the VDAC N-terminal region within
the channel pore, yet biochemical and functional studies reveal that the
N-terminal domain is cytoplasmically exposed (see Section 2.2). Thus, it
has been proposed that upon apoptosis induction and concomitantwith
VDAC1 oligomerization, the amphipathic N-terminal domain is
translocated from the pore interior into a newly formed oligomeric
structure [49,224,238] (Fig. 4D). This relocated N-terminal domain
converts the hydrophobic pore into a pore that instead presents a hy-
drophilic environment, conducive to the passage of Cyto c and other
apoptotgenic proteins across the OMM [49,62,154,224,238] (Fig. 4D).
This suggestion is supported by circular dichroism (CD) and NMR stud-
ies showing that a synthetic peptide corresponding to VDAC1 residues
2–20 exists as an unstructured peptide in aqueous solvent yet forms a
well-ordered α-helix from residues 5–16 in SDS [242]. Moreover, the
glycine-rich sequence in the N-terminal domain was shown to provide
theﬂexibility required for its translocation out of the internal pore of the
channel [49]. The location and translocation of the VDAC1 N-terminal
domain as a target for anti-apoptotic proteins were demonstrated by
site-directed mutagenesis and cysteine substitution, together with a
thiol-speciﬁc cross-linker [49]. These studies showed that the VDAC1
N-terminal region exists in a dynamic equilibrium, located within the
pore or exposed outside the β-barrel, and that this translocation to the
cytsol is required for binding of HK and anti-apoptotic proteins, Bcl2
and Bcl-xL [49,62,196,197].
5. VDAC1 over-expression and cell death
5.1. Exogenous VDAC over-expression induces cell death
Numerous studies using silencing or over-expression approaches
suggest that the expression level of VDAC1 plays a critical role in
mitochondria-mediated apoptosis [2,62,121,184,189–191,223,233].
Over-expressing human, murine, yeast, Paralichthys olivaceus, or rice
VDAC was found to induce apoptotic cell death regardless of cell type
[121,184,189–191] by an as yet unknown signaling pathway. Such
VDAC1 over-expression resulted in apoptosis, as reﬂected by cell stain-
ing with annexin V, membrane blebbing, chromatin condensation and
fragmentation, and Cyto c release [223]. It was demonstrated that
VDAC1 over-expression is associated with VDAC1 oligomerization,
shifting the equilibrium toward the oligomeric state and allowing the
release of pro-apoptotic proteins, leading to cell death [62,223,233]
(see Section 4.4). VDAC1 over-expression-induced cell death wasprevented by RuR [121,185], Bcl2, DIDS [191] or by over-expression
of HK-I [121,184,243], with all these agents directly interacting
with VDAC1. These results show that the cellular expression level and
oligomerization state of VDAC1 are crucial factors in the process of
mitochondria-mediated apoptosis.
5.2. Apoptosis stimuli induce VDAC1 over-expression — a new mode of
action
Several studies demonstrated an increase in VDAC1 expression
levels following apoptosis induction by pro-apoptotic drugs or condi-
tions (Table 1). For example, up-regulation of VDAC1 expression was
observed in three different acute lymphoblastic leukemia (ALL) cell
lines (697, Sup-B15, and RS4; 11) following prednisolone treatment,
an observation that can be explored for predicting eventual outcome
in childhood ALL [244]. VDAC1 over-expression was observed in a
cisplatin-sensitive cervix squamous cell carcinoma cell line (A431)
when exposed to cisplatin, while in a cisplatin-resistant cell line
(A431/Pt) the treatment resulted in down-regulation of VDAC1 [245].
Furthermore, in human malignant melanoma cells, arbutin (hydroqui-
none-O-beta-D-glucopyranoside), a tyrosinase inhibitor and a potential
anti-cancer agent, was found to induce apoptosis by causing VDAC1
over-expression [246,247]. Somatostatin, reported to be useful in the
treatment of advanced prostate cancer, was found to up-regulate the
expression of VDAC1 and VDAC2 in the LNCaP prostate cancer cell line
[248]. Up-regulation of VDAC1 has been reported upon UV irradiation
of apoptosis-sensitive cells [249]. In addition, ROS was found to induce
up-regulation of VDAC that could be prevented by the ROS chelator,
epigallocatechin [165]. The induction of VDAC1 over-expression and
increase in cellular Ca2+ levels by cisplatin is presented in Fig. 5.
Importantly, the causal relationship between VDAC1 expression
levels and sensitivity to various treatments was emphasized in several
studies (Table 2). Melanoma cell lines that were relatively resistant to
apoptosis induction by oblimersen sodium (G3139), an anti-sense
oligonucleotide that directly interacts with VDAC to reduce its channel
activity and evaluated as a possible treatment for several types of cancer
[250], were found to express lower levels of VDAC1 than did G3139-
sensitivemelanoma518A2 andother cell lines [250]. Similarly, reducing
VDAC1 expression by siRNA efﬁciently prevented cisplatin-induced
apoptosis and Bax activation in NSCLC [187], and inhibited selenite-
induced PTP opening in HeLa cells [251]. The anti-cancer activity of
furanonaphthoquinones (FNQs) was increased upon VDAC1 over-
expression and decreased upon silencing of VDAC1 expression by
siRNA [163,252]. Recently, it was also shown that over-expression of
VDAC1 sensitized carcinoma cells to apoptosis induced by cisplatin,
mechlorethamine, and its derivative, melphalan [253]. Thus, following
apoptosis induction by various agents, VDAC1 over-expression was ob-
served. This, together with the correlation between drug efﬁcacy and
VDAC1 expression level, all suggest that the activities of numerous
anti-cancer drugs and treatments are mediated via regulating VDAC1
expression levels.
Recently, based on the ﬁndings that several cancer drugs and treat-
ments that act by inducing apoptosis lead to up-regulation of VDAC1
expression levels [244–248,254], an additional mode of action for
apoptosis stimulus involving increased expression of VDAC1 was
proposed [223]. Moreover, it has been argued that apoptosis-inducing
agents act by increasing [Ca2+]i and that this in turn leads to an up-
regulation of VDAC1 expression. This is followed by VDAC1 oligomeri-
zation, Cyto c release and ﬁnally, cell death [223] (Fig. 5).
Although different apoptosis inducers elicit cell death via different
mechanisms, all induce VDAC1 over-expression in Ca2+-dependent
manner [223], raising the possibility that elevating [Ca2+]i represents
a common mechanism for the various apoptosis stimuli, subsequently
leading to elevation in VDAC1 expression. This new mechanism of
pro-apoptotic drug action, namely enhancement of VDAC1 expression,
provides a platform for developing a new class of anti-cancer drugs.
Table 1
Compounds and conditions targeting VDAC1 or its expression.
Drugs Cancer cell type Mode of action References
Prednisolone Acute lymphoblastic leukemia (ALL) cell line Up-regulation of VDAC1 expression [244]
Cisplatin Cervix squamous cell carcinoma cell line (A431) Up-regulation of VDAC1 expression [245]
Arbutin (hydroquinone-O-β-D-glucopyranoside) Human malignant melanoma cells (A375) Up-regulation of VDAC1 expression [246,247]
Hepatitis E virus ORF3 protein Hepatoma cells Up-regulatation of VDAC1 expression [239]
Radiation B cell mouse lymphoma (LYas) Up-regulation of VDAC1 expression [254]
Mechlorethamine and its derivative, melphalan Cervical and colon carcinoma cells Up-regulation of VDAC1 expression [253]
Erastin Engineered tumorigenic Human foreskine ﬁbroblasts
(BJ-TERT/LT/ST/RASV12)
Oxidative species generation; alteration of OMM
permeability
[424]
Oblimersen (G3139) Melanoma cells (518A2) Induces mitochondria-mediated apoptosis; reduces
VDAC1 channel conductance
[119,250]
Furanonaphthoquinones (FNQs) Cervical cancer (Human Hela cell line) H2O2 production [163]
Methyl Jasmonate (MJ) Inhibits allograft tumor in mice (CT-26 tumor), induces
cell death in murine colon carcinoma (CT26), melanoma
(B16) and B-cell leukemia (BCL1) cell lines
Disruption of HK-VDAC1 interaction [291]
Vacuolating cytotoxin Human gastric carcinoma (AGS cell line) Apoptotic process is associated with the up-regulation
of Bax/VDAC1
[425]
2558 V. Shoshan-Barmatz et al. / Biochimica et Biophysica Acta 1848 (2015) 2547–25756. ER-mitochondria Ca2+ transport, VDAC and apoptosis
Ca2+ originating from the ER has been shown to be a potent death-
inducing signal [255]. The interplay between ER and mitochondriaFig. 5. Apoptosis inducers up-regulate VDAC1 expression and elevate cytosolic Ca2+. A. Apopto
dicated concentrations of cisplatin (16 h) and VDAC1 expression levels were analyzed by immu
increase. B. Apoptosis inducers up-regulate VDAC1 expression and elevate cytosolic Ca2+. For m
night and then treated with the indicated compounds, followed by incubation with Fluo-4. Cel
posedmodel for the role of increasing [Ca2+]i in VDAC1 expression and subsequent cell death i
into the model presented in (a). This model suggests that apoptosis induction by a given stimu
The increase inVDAC1 expression shifts the equilibrium towards theVDAC1 oligomeric state, all
When VDAC1 is over-expressed by transfection (b), no change in intracellular Ca2+ level was ob
not for the subsequent steps leading to VDAC1 oligomerization, Cyto c release and ﬁnally, apo
promoter directly or by stimulating the activity of transcription factors (c).mediated Ca2+ signaling is a determinant of cellular fate through the
control of apoptosis and autophagy [256]. Release of Ca2+ from the ER
via inositol-1,4,5-trisphosphate receptors (IP3Rs) has been observed in
models of apoptosis and has been implicated directly in mitochondrialsis inducers up-regulate VDAC1 expression levels. HeLa cells were incubated with the in-
noblotting followed by quantitative analysis, as presented in the bottom of the blot as fold
onitoring [Ca2+]i levels, HeLa cells were seeded on black Cell Carrier 96-well plates over-
l ﬂuorescence was recorded using the Operetta. Representative images are shown. C. Pro-
nduction. Previously reported results [223] and those presented here (A, B), are integrated
lus causes an increase in intracellular Ca2+ levels, leading to enhanced VDAC1 expression.
owing for Cyto c release from the innermitochondria space, leading to apoptotic cell death.
served [223], suggesting that Ca2+ is required for induction of VDAC1 over-expression and
ptotic cell death. Ca2+-induced VDAC1 expression may result from activating the VDAC1
Table 2
VDAC1 expression level in cancer cell lines and tumors.
Cancer types (tumor/cell line) VDAC-1
expression
Detection methods Comments Reference
Adrenocortical carcinoma (ACC) (Human
SW13 and H295R)
Up-regulation Western blot Cytotoxic effect in ACC [426]
Cervical cancer (Hela cell line) Up-regulation Western blot, immunohistochemistry Increases sensitivity Furanonaphthoquinones [395]
Cholangiocarcinomas (CC) (SKC cell line) Up-regulation Microarray, northern hybridization Genetic & gene expression alterations may be
relevant to the sarcomatous epitehial–
mesenchymal transition (EMT) in CC
[390]
Esophageal Cancer (tumor) Down-regulation qRT-PCR, microarray Proposed as the molecular mechanism associated
with progression of esophageal cancer
[427]
Lung adenocarcinoma (tumors) Up-regulation Mass spectrometry
immunohistochemistry
The molecular mechanisms behind tumor
progression
[396]
Myeloma (CD45+ U266 tissue) Up-regulation Semi-quantitative RT-PCR, Western blot Sensitizes myeloma cells for apoptosis [394]
Malignant melanoma (UACC903 cell line) Down- regulation cDNA microarrays Resistant to apoptosis [428]
Malignant melanoma (UACC903(+6) cell line) Up-regulation cDNA microarrays Sensitivity to apoptosis [428]
Non-small cell lung cancer (NSCLC tumor) Up-regulation Gene expression meta-analysis Aggressive tumor behavior [397]
Gastric cancer (tumor) Up-regulation Western blot Biomarker for tumor progression [391]
Ovarian and endometrial cancer
(OV-TRL12B, EN-TRL 67 T cell line)
Up-regulation Western blot Proposed as molecular and biological mechanisms of
ovarian/endometrial tumor progression
[429]
Lung cancer tumors and cell lines Up-regulation Western blot Tumor and healthy tissues from the same patient
were compared
[421]
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cade, IP3R and VDAC were identiﬁed as two important actors in the
transmission of Ca2+ signals between the ER and mitochondria [11,40,
118,258]. Transient expression of VDAC enhanced the amplitude of
agonist-dependent increases in mitochondrial matrix Ca2+ concentra-
tion by allowing the fast diffusion of Ca2+ from ER release sites to the
inner mitochondrial membrane [118].
The speciﬁc sites of physical association between the ER and mito-
chondria, known as mitochondria associated membranes (MAMs), in-
clude VDAC among the proteins present at these junctions [259]. The
mitochondrial chaperone glucose-regulated protein 75 (grp75) has
been proposed to mediate the molecular interaction of VDAC1 with
the ER Ca2+ release channel, IP3R, and that a chaperone-mediated con-
formational coupling of the proteins enables better transfer of the Ca2+
ions from the ER to the mitochondria [260]. It was reported that in a
cell-free system containing puriﬁed mitochondria, ER vesicles, IP3R,
and VDAC1, PTP activity was identiﬁed as being involved in the ER-
triggered pro-apoptotic mitochondrial membrane permeabilization
process [258]. It has been recently established that VDAC1 (but not
isoforms 2 or 3) selectively interacts with IP3Rs and is preferentially
involved in the transmission of low amplitude apoptotic Ca2+ signals
to mitochondria [261]. The involvement of VDAC1 in ER-mitochondria
Ca2+ cross-talk places VDAC1 at a crucial position on the route transfer-
ring Ca2+ signals from the ER tomitochondria, and thus couples ER and
mitochondrial functions [261]. The emerging role of dysregulated mito-
chondrial Ca2+ homeostasis in tumorigenesis has also received increas-
ing attention [262–265]. The reduction of mitochondrial Ca2+ uptake in
cancer cells can decrease activation of the mitochondrial intrinsic
apoptosis pathway, and thus favors cancer cell survival and tumor
metastasis [266]. It has been demonstrated that the release of Ca2+
from ER stores inducedmitochondrial Ca2+ accumulation and triggered
cell death in human cervix and colon carcinoma cell lines [258]. ER
stress also induced mitochondrial membrane permeability that is regu-
lated by members of the Bcl-2 family of proteins [124] that also interact
with VDAC1 [192,197].
7. Reprogramming energy metabolism in cancer and the
Warburg effect
Tumor cells thrive in environments that would be hostile to their
normal counterparts. Survival depends on the selection of cells that har-
bormodiﬁcations of gene regulation that shifts the balance between the
cell cycle and apoptosis and/or that involve plasticity of the metabolic
machinery. Metabolism and cell growth are two cellular processesthat are tightly linked and regulated [267]. In addition, tumor cells
maintain high ATP/ADP as well as NADH/NAD+ ratios, so to assure
that ATP levels are never limited as ATP depletion would present an
unsustainable metabolic stress for tumor cells, being associated with
necrotic death in some cell types [268].
In recent years, evidence has accumulated indicating a correlation
between alterations in metabolism and cancer. It is well known that
cancer cells undergo signiﬁcant metabolic adaptations corresponding
to adjustments in energy metabolism so as to fuel cell growth and
division [269–271]. The classic bioenergetics phenotype of cancer cells
usually displays enhanced aerobic glycolysis, providing precursors for
the synthesis of lipids, proteins and DNA and a new redox balance.
Whereas normal cells produce energy by a low rate of glycolysis follow-
ed by oxidation of pyruvate inmitochondria, malignant cancer cells typ-
ically display high rates of glycolysis even when fully oxygenated, an
observation termed aerobic glycolysis [269]. Cancer cells are, moreover,
subject to suppressed mitochondrial respiration, despite the fact that
glycolysis is a less energy-efﬁcient pathway, a phenomenon known as
the Warburg effect [269–271]. To increase glycolysis, cancer cells up-
regulate the transcription of genes involved in the glycolytic pathway
(i.e., glucose transporters, and glycolytic enzymes). Cancer cells actually
use a combination of both glycolysis and mitochondrial respiration to
produce energy, and may vary in regard to the preferential use of
these pathways, being in some cases either more glycolytic/less oxida-
tive or less glycolytic/more oxidative, depending on the prevalent
normoxic or hypoxic environmental conditions and their capacities to
express adequate levels of oncogenes and tumor suppressor gene prod-
ucts for cell growth [272–274]. Shifting the balance between the two
processes via the use of glycolytic and/or mitochondrial enzyme
inhibitors could be an interesting starting point in the search for new
anti-cancer agents.
TheWarburg effect likely provides the vastmajority of cancerous tu-
mors with a number of beneﬁts, such as precursors for the biosynthesis
of nucleic acids, phospholipids, fatty acids, cholesterol, and porphyrins.
A second advantage of the Warburg effect is likely involved in both
tumor protection and invasion. Tumor cells produce lactic acid via gly-
colysis and transport it out of the cell, creating a layer of low pH. This
is proposed to protect tumors against attacks by the immune system
while causing damage to normal surrounding cells, thus preparing
them for invasion. Additionally, the Warburg effect assures a longer
tumor survival time if oxygen becomes limiting [270]. Moreover, the
cancer-associated abnormalities in glucose metabolism enhance cellu-
lar resistance to apoptosis, with mitochondria being found to play a
key role in this process [275–279].
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is attributed to marked over-expression of mitochondrial-bound HK
that is considered the rate-limiting enzyme of glycolysis [2,280–282].
HK likely plays a key role in cell growth rate and survival of cancer
cells and is probably a major factor underlying the Warburg effect
[273,281,283–285]. The metabolic re-programming of the cancer cell
includes HK interacting with VDAC1, with this interaction offering sev-
eral advantages to cancer cells [2,6], as outlined below (see Section 8.1).
Mitochondria regulate glycolytic ﬂux with the actions of the TCA
cycle and ATP synthase to balance the energy requirements of the
tumor cell with biochemical requirements for metabolites (i.e., the
anaplerotic and cataplerotic pathways, respectively) or metabolite pre-
cursors that are required by the tumor [2,281,282,285]. Thus, both the
glycolytic pathway and other seminalmetabolic pathways, like the pen-
tose phosphate shunt, are regulated via the energy-coupling resulting
from the formation of the VDAC1-bound HK complex.
Yet another linkbetweenVDAC1and the regulation ofmetabolism is
reﬂected by the regulation of HK-VDAC1 complex formation by Akt
[286,287] and glycogen synthase kinase 3 beta (GSK3β). In addition, it
was shown that an increase in the amount of free cytoplasmic tubulin
induced by microtubule-destabilizing agents decreased VDAC conduc-
tance and mitochondrial membrane potential (ΔΨ(m)). Tubulin-
dependent suppression of ΔΨm was further potentiated by protein
kinase A activation and GSK3β inhibition. Tubulin-dependent suppres-
sion of ΔΨm is universal for all three VDAC isoforms [16]. HK also
functions as a regulator of cell viability and apoptosis by preventing
the release of Cyto c from the mitochondria [2,280–282,288] (see
Section 8.1).Fig. 6. Schematic representation of VDAC1 as a hub protein and its associated proteins. Protei
pro-apoptotic proteins tBid, Bax, TPSO/PBR, and Nek1 (NIMA-related protein kinase 1), and the
proteins, like aldolase, GA3PD,HK-I, HK-II, ANT andmtCK; (c) structural and cytoskeleton prote
protein 74, also known as mtHSP70/GRP75/mortalin), MAP2, gelsolin and adseverin; and (d) o
induced chloride channel), CRYAB (α-crystallin B), SOD1, eNOS,α-synuclein and C-Raf. The pro
are over-expressed in cancer are highlighted.8. VDAC1-interacting proteins
VDAC1 at the OMM serves as a hub protein interacting with diverse
sets of cytosolic and mitochondrial proteins which, together with
VDAC1,mediate themetabolic and signaling cross-talk between cytosol
and mitochondria (Fig. 6). Some of these interacting proteins are also
highly expressed in many cancers, such as Bcl2, Bcl-xL and HK. Thus,
VDAC1 provides structural and functional anchoring sites allowing the
regulation of metabolic and apoptotic processes in normal and cancer
cells. VDAC1 displays binding sites for glycerol kinase [289], HK [184,
233,243,290–292], creatine kinase [293], C-Raf kinase [294], ANT
[295], the peripheral benzodiazepine receptor (also known as TSPO,
translocator protein) [296], tubulin [297], the dynein light chain,
PBP74 (heat-shock protein peptide-binding protein 74) known also as
mtHSP70/GRP75/mortalin, the ORDIC channel, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) [11], actin [298] and gelsolin
[299], as well as Bcl-2 family members [181,196,197,300,301]. Interac-
tion with apoptosis-regulating proteins, such as HK and Bcl-2 family
members, make VDAC1 a key protein in apoptosis regulation [7].
Here, we focus on those VDAC1-interacting proteins showing modiﬁed
levels of expression in cancer cells.
8.1. Interaction of VDAC1 with HK regulates cancer cell bioenergetics and
apoptosis
8.1.1. HK expression and bioenergetics regulation in cancer cells
One of the signature phenotypes of highly malignant, poorly
differentiated tumors is their high rate of glycolysis, leading to enhancedns interacting with VDAC1 (see Section 7) include: (a) Apoptogenic proteins, namely the
anti-apoptotic proteins Bcl2, Bcl-xL; (b)metabolism and energy production and regulation
ins, such as actin, tubulin, Tctex-1/DYNLT1 and PBP74 (heat-shock protein peptide-binding
ther proteins with diverse functions, such as ORDIC (outwardly rectifying depolarization-
teins involved inmore than one function are placed in the overlapping areas. Proteins that
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marked over-expression of VDAC1-bound HK in cancer cells [152,282,
303,304]. HK thus lies at the apex of the glycolytic pathway that provides
the metabolic intermediates required by the biosynthetic pathways on
which a transformed cell places heavy demand [283,285]. Due to a
higher rate of glycolysis in the tumor cell, the glucose consumption of
cancer cells is greater than that of non-malignant cells. As such, inhibi-
tion of glycolytic energy production could provide a framework for the
discovery of new anti-cancer compounds.
HK catalyzes the rate-limiting step in glycolysis, namely the ATP-
dependent phosphorylation of glucose to glucose-6-phosphate (G-6-P).
The mitochondria-bound isoforms HK-I and -II were found to be over-
expressed in many cancers, including colon, prostate, lymphoma, glioma,
gastric adenomas, carcinomas and breast cancers [152,283]. The elevated
levels ofmitochondria-boundHK in cancer cells is suggested to play a piv-
otal role in promoting cell growth and survival in rapidly growing, highly
glycolytic tumors and in protecting against mitochondria-mediated cell
death [281]. As presented below, the association/dissociation of HK
with/from VDAC1 and the switching of VDAC1 between an ‘open’ and a
‘closed’ state regulate the metabolic cross-talk between mitochondria
and the cytosol [2,181]. This control is important for maintaining the
mitochondrial respiration and glycolysis equilibrium at the heart of the
energetic and metabolic homeostasis of the cancer cell.
8.1.2. VDAC1 is the mitochondrial-binding site of HK
The interaction of HK with the mitochondria, and speciﬁcally with
VDAC1, has shifted our view of HK as predominantly fulﬁlling a meta-
bolic role to one of regulating the apoptotic responsiveness of the cell,
making the VDAC1-HK complex a target for therapeutic purposes
[93,181,184,233,243,288,290–292,305]. The interaction between HK-I
and VDAC1 was ﬁrst demonstrated in a reconstituted system where
HK-I decreased the channel conductance of VDAC1, an effect that was
reversed by G-6-P, shown to detach HK from isolated mitochondria
[243] (Fig. 7). The interaction between HK-I and VDAC1 was againFig. 7.Hexokinase binding tomitochondria and to bilayer-reconstituted VDAC1 that reduce its c
HK-I-GFP fusion protein was expressed in HeLa cells. Confocal ﬂuorescence microscopy show
distribution, and is co-localized with the mitochondrial marker, MitoTracker (right panel). Im
bar = 5 μm. B. HK-II was cloned and expressed in Escherichia coli and puriﬁed using Ni-NTA. V
VDAC1, in response to voltage steps: 0 to 10 mV (I) or 0 to 40 mV (II), were recorded before
C. The effect of humanHK-II on VDAC1 as a function of voltage, from 60 to−60mV. The average
at 10 mV. Recordings were taken before (●) and after (○) the addition of HK-II.demonstrated by co-immunoprecipitation [155]. The co-localization of
HK-I with each of the three isoforms of VDAC1 was demonstrated
using two-color stimulated emission depletion (STED) microscopy
[306]. HK-I-VDAC1 interaction could be abrogated upon mutagenesis
of a single VDAC1 residue (Glu73, Glu202 or Glu65), resulting in the
elimination of HK-mediated protection against apoptosis and channel
closure [121,184]. N-terminally-truncated VDAC1 is incapable of
binding HK [62] or Bcl-xL [196]. Moreover, when the N-terminal region
α-helix structure in VDAC1 was perturbed, binding of HK was reduced
[49]. It was proposed that the N-terminal region of HK-I is inserted
into the channel pore, where it interacts with the N-terminal region of
VDAC1 [307]. It should be noted that there is strong residue conserva-
tion between the HK-I and HK-II N-termini, and that such conservation
is not shared by the other two non-bound mitochondrial HK isoforms,
HK-III and HK-IV.
Finally, the VDAC1-HK interaction was shown to be regulated by
phosphorylation as occurs when glycogen synthase kinase 3β (GSK3β)
is up-regulated [292] in a process mediated via protein kinase C (PKC)
[93], as well as in response to the cholesterol content of the OMM [93].
8.1.3. HK protection against cell death is mediated via interaction with
VDAC1
Both in vitro and in vivo studies have shown that elevated levels
of mitochondria-bound HK in cancer cells also protect against
mitochondria-mediated apoptosis via direct interaction with VDAC1.
Mitochondrially-associated HK has been shown to protect HeLa and
HEK cells from entering apoptosis [62,121,152,184]. This protection
was related to a blockade of the interaction of the pro-apoptotic protein
Bax with VDAC1 [152]. Moreover, over-expression of HK-I or HK-II in
tumor-derived cell lines suppressed STS-induced Cyto c release and
apoptosis [121,243,290]. A decrease in apoptosis and an increase in
cell proliferation have also been reported to be induced byHK-II expres-
sion in the NIH-3 T3 [308] and rat 1a cell lines [303]. Importantly, muta-
genesis studies revealed that single mutations or N-terminal truncationhannel conductance. A. To demonstrate VDAC1-mediated HK-I binding tomitochondria, a
s that HK-I-GFP ﬂuorescence (left panel) is punctuated, as expected for mitochondrial
ages show representative microscopic ﬁelds from one of three similar experiments. Scale
DAC1 was reconstituted into a PLB (as described in Fig. 2), and channel currents through
and after the addition of human HK-II (2 μg/ml). The dashed lines indicate zero current.
steady-state conductance at a given voltagewas normalized to the conductance recorded
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channel closure in a reconstituted membrane system [62,121,184,288].
In addition, binding of HK-II to mitochondria inhibited Bax-induced
Cyto c release and apoptosis [305]. Finally, VDAC1-based peptides were
found to interact with puriﬁed HK and when expressed in cells over-
expressing HK, prevented the anti-apoptotic activity of HK [290].
8.1.4. The interaction of HK with VDAC1 offers advantages to cancer cells
Severalmechanisms bywhichHKbinding to VDAC1 protects against
apoptosis and promotes cell survival can be considered. These include
controlling energy and metabolic homeostasis, as well as preventing
VDAC1-mediated Cyto c release and shielding VDAC1 from pro-
apoptotic factor binding, thus offering the tumor cell protection from
cell death in a synergistic manner. At the same time, disruption of this
interaction provide a strategy to interfere with cancer cell growth (see
Section 10.2.2). The advantages to cancer cells of HK binding to
VDAC1 include:
i. Production and access to energy and metabolites — HK bound to
VDAC1 provides cells with metabolic advantages that allow for
enhanced cell growth [285]. Anchoring of HK to VDAC1 offers the
enzyme direct access to mitochondrial sources of ATP and greater
afﬁnity for Mg2+-ATP [18,309]. HK bound to the cytosolic face of
VDAC1 acts as a gate, regulating the trafﬁc of various metabolites
through the VDAC1 channel [243]. In addition, VDAC1-bound HK is
less sensitive to inhibition by its product, G-6-P [243], thus avoiding
product inhibition. The HK-VDAC1 interaction thus increases energy
and metabolite production of the high energy-demanding cancer
cells, allowing for maintenance of a high glycolytic ﬂux rate in tu-
mors [243,310].
ii. VDAC1-bound HK acts as an anti-apoptotic protein — Accumulated
evidence demonstrated that HK-I and HK-II also function as anti-
apoptotic proteinswhenbound toVDAC1,while their detachment en-
abled activation of apoptosis [93,181,184,233,243,288,290–292,305].
Disruption of HK binding to VDAC1 bymutation in VDAC1 or by addi-
tion of VDAC1-based peptides diminished HK anti-apoptotic activi-
ty [290]. HK interaction with VDAC1 protected against activation of
apoptosis by Bax or Bak [93,286,305]. The detachment of HK-II from
the mitochondria was found to markedly potentiate the onset of
caspase 2-induced mitochondrial damage [311].
iii. Regulation of ROS production by HK — ROS act as second messen-
gers in cell signaling and are essential for multiple biological pro-
cesses in normal cells. However, ROS can also provoke damage to
multiple cellular organelles and processes [312]. ROS production is
usually increased in cancer cells due to oncogene activation [313].
Mitochondria-associated HK was shown to reduce mitochondrial
ROS generation [151], with HK-I and HK-II reducing intracellular
levels of ROS [149]. Moreover, expression of both HK-I and HK-II
was found to protect against oxidant-induced cell death [150,152].
Thus, detachment of HK from VDAC1 could lead to increased ROS
generation and release to the cytoplasm, thereby activating cell
death.
iv. Stabilization of both HK and VDAC1 — VDAC1, containing an odd
number of β-strands, presents conformational intrinsic instability
within the ﬁrst four β-strands (β1–4), relative to other VDAC1 re-
gions [46]. In silico studies of the VDAC1–HK-I interaction predicts
that both proteins attain a more stable state through protein-
protein interactions [307]. It is proposed that upon binding with
the N-terminal helix of HK-I, VDAC1 acquires higher stability via
the formation of a network of chemical bonds both due to direct
protein-protein contacts and to hydrogen bonds mediated by an
ATP molecule and a Mg2+ ion [307]. Stabilization of VDAC1 (over-
expressed in cancers; Section 10.1) by HK is important for VDAC1
to fulﬁll its function in energy and metabolism homeostasis.
v. Increased synthesis and uptake of cholesterol — Cancer cells have
been shown to exhibit a 2–10-fold increase in mitochondrialcholesterol content, in comparison to liver mitochondria [77]. It
has been proposed that the increased binding of HK to the mito-
chondria of cancer cells may play a role in mediating increased syn-
thesis and uptake of cholesterol into the mitochondria of cancer
cells [93]. It has been shown that disruption of VDAC1-hexokinase
binding in cancer cells resulted in a decrease of cholesterol content
of the OMM and increased sensitivity to mitochondrial matrix
swelling, suggesting that VDAC1 inﬂuences cholesterol distribution
in the OMM (see Section 3.2), and may impact oxidative phosphor-
ylation and apoptosis sensitivity in cancer cells [83].
Many attempts to target glycolysis via inhibiting HK, including via
treatment with 2-deoxyglucose (2-DG), 3-bromopyruvate (3-BP), an
alkylating reagent that reacts with the free SH groups of cysteine
residues in certain proteins that also targets GAPDH, or lonidamine, a
derivate of indazole-3-carboxylic acid [314]. 3-BP has been proposed
to covalent modify HK-II, leading to its dissociation from mitochondria
and apoptosis induction [315]. However, the use of glycolytic inhibitors
for cancer treatment raises potential concerns and challenges as these
compounds are not very potent and because certain normal tissues, in-
cluding brain, retinae, and testis, use glucose as the main energy source
[314]. On the other hand, the VDAC1-HK interaction was identiﬁed as a
promising target for concomitant anti-cancer therapy [314].
8.2. Interaction of VDAC1 with Bcl-2 family members
One of the hallmarks of cancer cells is their resistance to apoptosis.
This can be acquired through a variety of strategies, including
quenching of the mitochondrial apoptotic pathway by over-expression
of anti-apoptotic proteins of the Bcl-2 family. This in turn contributes
to tumor initiation, disease progression, drug resistance [300,301,
316–319] and cellular responses to anti-cancer treatments [320,321].
The Bcl-2 family of proteins function as central regulators of apoptosis
in mammals and include proteins that both up- or down-regulate
apoptosis [320,321]. The family comprises close to 25 pro-apoptotic
(e.g. Bid, Bax, Bim and Bak) or anti-apoptotic (e.g. Bcl-2 and Bcl-xL)
members. All of these proteins are characterized by the presence of
Bcl2 homology (BH) domains and are classiﬁed by sequence homology
based on the presence of up to fourα-helical domains, termed Bcl-2 ho-
mology (BH)1 to 4 domains [300,321]. These can be further sub-divided
into three main groups, based on the BH domain(s) they contain and
their function. Anti-apoptotic family members, such as Bcl-2, Bcl-xL,
Mcl-1, Blf1 and A1, contain four BH domains (BH1-4), whereas some
pro-apoptotic family member proteins, such as Bax and Bak, contain
three BH domains (BH1–3). Others family members, such as Bid,
Bim, Bad, Bik, Noxa, PUMA and Bmf, contain only one BH3 domain
[175,300,321–326].
The mechanisms by which Bcl-2 family proteins regulate apoptosis
are still not fully understood, although it is well established that their
activities are mediated via interactions with mitochondria and by
controlling OMM permeability [327]. Accumulated evidence indicates
that the regulation of apoptosis by pro- and anti-apoptotic members
of the Bcl-2 family is mediated via their interactions with VDAC1
[62,187,195,197,290,328–330]. VDAC1 has been shown to interact
with Bax/Bak, Bcl-2 [197], Bcl-xL [47,192,195–197,328,330,331] and
with Bax and Bim [220,328]. It was also reported that both pro-
apoptotic Bax and anti-apoptotic Bcl-xL interact simultaneously with
the putative loop regions of human VDAC1 to create a tertiary complex
[234,332]. Bax was also found to increase VDAC1 conductance [219].
Additionally, Bcl-2 and Bcl-xL block As2O3-induced VDAC1 dimerization
[183]. BH4 oligopeptides derived from Bcl-2 and Bcl-xL are alone able to
inhibit both VDAC1 activity in liposomes, even in the presence of
pro-apoptotic protein such as Bax, and prevent ΔΨ(m) loss in isolated
mitochondria [330]. Recently, an interaction of Bcl-2 and Bcl-xL with
VDAC1 and the subsequent reduction of the channel conductance of na-
tive but not mutated reconstituted VDAC1 was shown [196,197]. The
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not mutated VDAC1 [196,197]. Moreover, it was shown that Bcl-xL
can modify the oligomerization status of VDAC1 by shifting the
equilibrium from the trimeric to the dimeric state [47,195].
In contrast, the multi-BH domain-containing pro-apoptotic mem-
bers Bax and Bak are the essential gateways for OMM permeability
and it has been suggested that both physically interact with VDAC1 to
yield a complex with permeability 4–10 times larger than that of
VDAC1 alone [194,228]. Consequently, recombinant pro-apoptotic
proteins Bax and Bak accelerate the opening of VDAC1 channels in
liposomes and induce Cyto c release. Bcl-xL and anti-VDAC1 antibodies
prevent this release [182]. Bax and VDAC1 reconstituted into liposomes
were shown to form a channel with higher conductance than VDAC1
alone, with this increase being prevented by Bcl-xL [194]. In agreement,
VDAC1-deﬁcient mitochondria from mutant yeast did not exhibit Bax/
Bak-induced loss inmembrane potential or Cyto c release [192]. In addi-
tion, cisplatin-induced activation of Bax was inhibited in VDAC1-
depleted cells [187,192], suggesting that VDAC1 is involved in
Bax-mediated apoptosis. A novel human BH3-only protein (designated
as Bop), which induces apoptosis in a BH3 domain-dependent manner,
mainly localized to mitochondria where its BH3 domain contacts the
loop regions of VDAC1 in the OMM. Puriﬁed Bop induced the loss of
ΔΨ(m) and the release of Cyto c. Bop uses its BH3 domain to contact
pro-survival Bcl-2 family members (Bcl-2, Bcl-xL, Mcl-1, A1 and
Bcl-w) which could inhibit Bop-induced apoptosis [333]. In addition,
Bax-VDAC interaction was also implied by the curcumin-induced mito-
chondrial translocation of Bax,whichwas blocked byDIDS [334], shown
to interact with VDAC and reduce its channel conductance [39]. The re-
quirement of VDAC2 for the pro-apoptotic activity of Bax has also been
demonstrated [335]. However, it was concluded that VDAC2 acts to
physically restrain BAK in the OMM in non-stimulated viable cells
[336]. It was also demonstrated that Bcl-x(S) over-expression resulted
in disruption of the VDAC2–Bak interaction leading to release of Bak
[36]. Bak was shown to incorporate into a VDAC2–Mtx1–Mtx2 multi-
protein complex in resting and dying cells. Upon TNF-induced apopto-
sis, Bak interacts with Mtx1 and promotes apoptosis [337]. In addition,
the death signals that displace VDAC2 from Bak were found to promote
Bak oligomerization and apoptosis [336]. Anti-VDAC antibodies
inhibited Bax- and Bim-induced release of Cyto c [182], whereas Bid
(but not Bax) was shown to modify the conductance of bilayer-
reconstituted VDAC channels [338]. In addition, As2O3-induced VDAC
dimerization in IM-9, a multiple myeloma cell line, was blocked by
supposed VDAC interaction with Bcl-2 and Bcl-xL [183].
Those VDAC1 domains involved in the interaction with Bcl-2 and
Bcl-Xl to confer anti-apoptotic activity were identiﬁed by site-directed
mutagenesis [196]. VDAC1-based peptides corresponding to the
VDAC1 N-terminal region and to other selected sequences interact spe-
ciﬁcally, in a concentration- and time-dependent manner, with Bcl-2
and Bcl-xL to prevent their anti-apoptotic activities [62,197,234,288,
290]. These results indicate that VDAC1 binds Bcl-2 family proteins to
regulate their effects on apoptosis and hence, interfering with such
interactions could facilitate apoptosis induction and enhance the thera-
peutic effect of chemotherapeutic agents.
8.3. Translocator protein (TSPO) and VDAC1
Translocator protein, also known as the peripheral benzodiazepine
receptor, is a highly hydrophobic 18 kDa protein mainly found in the
OMM [296,339]. TSPO is a multi-functional protein associated with the
regulation of cholesterol transport, steroidogenesis, porphyrin trans-
port, heme synthesis, apoptosis and cell proliferation [340]. TSPO is
over-expressed in different types of tumors and cancer cell lines, such
as CLL, breast, colorectal, prostate, ovarian, glioma and hepatocarcinoma
cancer cells, and its involvement in the modulation of cell proliferation
and tumorigenesis has been shown [341,342]. Moreover, increased
TSPO expression was correlated with an increased aggressive cancercell phenotype [341,343]. TSPO expression, nuclear localization, and
TSPO-mediated cholesterol transport into the nucleus are involved in
breast cancer cell proliferation and aggressive phenotype expression,
with TSPO expression correlating with advancing stages of this malig-
nancy [344]. TSPO is mainly found on the OMM [340,345], where it is
closely associated with VDAC [346]. It has been hypothesized that the
close association of TSPO with VDAC allows ROS generated via TSPO to
affect VDAC [296,347]. In addition, the reported grouping of TSPO mol-
ecules around VDAC, potentially reﬂecting TSPO polymerization [296,
348], could enhance the concentration of ROS generated by TSPO in
the proximity of VDAC, leading to apoptosis induction [296,349,350].
In addition, over-expression of TSPO inhibits VDAC1 expression, while
the silencing of TSPO increases VDAC1 expression in endothelial
cells [351].
PTP opening is regulated by different TSPO ligands, such as the
agonist Ro5-4864 and the antagonist PK11195, as well as by the endog-
enous ligand protoporphyrin IX [352,353]. PK11195 inducedmitochon-
drial depolarization and Cyto c release in primary CLL cells, with such
PK11195-induced apoptosis being inhibited by DIDS, also shown to in-
teract with VDAC, suggesting a possible interaction between TSPO and
VDAC [346,350,353]. However, the pro-apoptotic effects of PK11195
and Ro5-4864 were attributed to their interaction with low-afﬁnity
binding sites not directly related to VDAC [296].
8.4. Interaction of VDAC1 with and regulation by cytoskeletal proteins
In cancer, morphogenic changes are required for high proliferative
rates, the acquisition of inappropriate migratory patterns, and invasive
characteristics [354]. Alterations in the dynamics of the actin and tubu-
lin components of the cytoskeleton are well-known consequences of
signaling and the triggering of responses like apoptosis [355,356].
Mitochondria are dynamic organelles that actively travel along the
cytoskeleton within the cell. As such, many cytoskeleton-related pro-
teins interact with mitochondria, often via VDAC1.
Gelsolin (Gsn) is a Ca2+-dependent actin-regulatory protein that
modulates actin assembly and disassembly [357]. It is a cytoplasmic
protein yet is found in the mitochondrial fraction of cells [358].
Human Gsn has anti-apoptotic activity, whereas mouse Gsn exerts
either pro-apoptotic or anti-apoptotic activity, depending on the cell
type [299]. The anti-apoptotic activity of hGsn depends on its C-
terminal half (G5 segment) that prevents Cyto c release in isolated
mitochondria. hGsn and the G5 segment inhibit the channel activity of
VDAC1 and Cyto c release from liposomes through direct binding to
VDAC1 in a Ca2+-dependent manner [299,359]. On the other hand, ex-
pression of an N-terminally-cleaved Gsn product resulted in apoptosis
[360]. Gsn is a caspase 3 substrate and the cleaved fragment has been
implicated as an effector of apoptosis [361].
Adseverin or scinderin is amember of the calcium-regulated gelsolin
super-family affecting the actin polymeric state. Adseverin shares
60% identity with gelsolin but lacks the C-terminal extension [362].
Adseverin predominantly co-localizes with F-actin in bovine adrenal
medulla chromafﬁn cells, whereas gelsolin is diffusely localized in
such cells [363]. Adseverin is over-expressed in a cisplatin-resistant
human bladder cancer cell line (HT1376-CisR), with the increase
being more prominent in the mitochondrial than in the cytosolic
fraction [364]. Adseverin silencing by siRNA signiﬁcantly reduced
cell proliferation, with mitochondria-mediated apoptosis resulting
in HT1376-CisR cells. Immunoprecipitation analysis revealed that
adseverin interacts with VDAC1 in mitochondria and it was suggested
that in CDDP-resistant cells, the VDAC-adseverin interaction inhibited
mitochondria-mediated apoptosis [364].
Tubulin, a constituent of microtubules, is known to positionally
stabilize organelles, such as mitochondria, and to participate in
contacts between the ER and mitochondria. Within this framework,
speciﬁc association of VDAC1 with tubulin was shown by co-
immunoprecipitation [365] and by tubulin-induced VDAC1 closure
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bulin,whereby the negatively charged C-terminus of tubulin penetrates
into the positively charged VDAC1 pore, reducing its channel conduc-
tance [297,356]. Moreover, it was suggested that tubulin-dependent
closure of VDAC is important as a physiological process that sustains
the Warburg effect [356], with tubulin isoforms such as βIII-tubulin
playing a role in cellular adaptation to metabolic glucose deprivation
[366]. It was proposed that tubulin, VDAC1 and mitochondrial creatine
kinase (MtCK) are all members of a super-complex that is structurally
and functionally coupled to the ATP synthasome [367]. In a cellular
model of cardiomyocyte physiology, this complex presents a distinct
composition, where tubulin is replaced by HK and MtCK is absent,
thereby infusing mitochondrially generated ATP into the glycolytic
pathway and thus contributing to the Warburg effect [367].
Recently, it was suggested that VDAC1 and VDAC2 are most
inhibited by cytoplasmic free tubulin and that such interactions limit
mitochondrial metabolism in HepG2 cells, contributing to the Warburg
effect, with erastin reversing the tubulin–VDAC interaction [368]. MtCK
coupled to the ATP synthasome and to VDAC, as controlled by tubulin
βII, provides functional compartmentation of ATP in mitochondria and
energy channeling into the cytoplasm via the phosphotransfer network.
Tubulin is over-expressed in mitochondria of different human cancers
and non-neoplastic cell lines and could play a role in the regulation of
the mPTP [365]. βIII-tubulin expression is increased in mitochondria
of tumor cells and rescued tumor cells from cell death signals triggered
by DNA-targeting compounds, such as cisplatin, doxorubicin, and
etoposide [369,370].
G-actin directly and selectively binds to VDAC in yeast, as demon-
strated by surface plasmon resonance [371]. Moreover, the monomeric
form of G-actin could modulate gating of the Neurospora crassa VDAC
channel by reducing its conductance [298].
Finally, microtubule-associated protein 2 (MAP2) was shown to
bind VDAC by afﬁnity chromatography [372].
8.5. Other proteins interacting with VDAC1
8.5.1. MAVS
The mitochondrial anti-viral signaling protein, also known as IPS-1,
VISA, or Cardif [373] and localized in the OMM, participates in host
defense against viral infection by inducing interferon type I (IFN-I) pro-
duction [374]. MAVS induced caspase-dependent and IFN-independent
apoptosis in response to viral infection, indicating that mitochondrial-
locatedMAVSmight play an important role in virus-triggered apoptosis
induction, independent of its role in innate immunity [375]. Recently, it
was demonstrated that mitochondrial-located MAVS mediates its pro-
apoptotic activity by associating with VDAC1 and modulates VDAC1
protein stability via the ubiquitin-proteasome pathway [376]. MAVS
knockout mouse embryonic ﬁbroblasts (MEFs) displayed reduced
VDAC1 expression, while ectopic expression of MAVS resulted in
VDAC1 up-regulation and promoted apoptotic cell death [376].
8.5.2. SOD1
Superoxide dismutase 1 (SOD1) is a predominantly cytosolic
protein, with mutant SOD1 being present mostly in fractions enriched
formitochondria [377–379]. Mutant SOD1 associatedwith amyotrophic
lateral sclerosis (ALS) bound to bilayer-reconstituted VDAC1 and
inhibited its channel conductance [380]. Mutant SOD1 interacted with
Bcl2 protein and altered the normal interaction between Bcl-2 and
VDAC1, thus reducing OMM permeability [381].
8.5.3. eNOS
Endothelial NO synthase was also found to bind VDAC1. Such inter-
action ampliﬁed eNOS activity in an intracellular Ca2+-mediated
manner [382]. These ﬁndings suggest that the interaction between
VDAC and eNOS may be important for regulating eNOS activity and
modulation of VDAC [382].8.5.4. Other proteins
Several proteins were shown or proposed to directly interact with
VDAC1, These include Nek1 (NIMA-related protein kinase 1) [249,
383], aldolase [11], Tctex-1/DYNLT1 (dynein light chain) [384], MAP2
[372], CRYAB (α-crystallin B) [385] and α-synuclein [386].
In summary, VDAC1 serves as a central hub for responses to cellular
signaling as mediated by its interaction with over a dozen proteins
(Fig. 6). This may explain why VDAC1 is a highly conserved protein in
both the entire population and in patient somatic cells (see Section 10).
This ﬁnding indicates that VDAC1 is under strong purifying selection,
meaning that mutation of the encoding gene is less tolerated than are
mutations in most other genes.
9. Alterations in VDAC1 expression or sequence in cancers
9.1. VDAC1 expression in cancer cell lines and tumors
Human tumors are riddledwith genomic alterations that include not
onlymutations that disrupt awide spectrumof genes but also those that
affect proteins expression levels. While deep sequencing methods are
widely accepted as a means to detect and analyze cancer biomarkers
[387], other cancer-associated changes are not mutation-related but
rather appear as alterations in the expression or post-translational
modiﬁcation of marker proteins [388]. Histological indicators of cellular
morphology have also been used for diagnostic and prognostic
assessment of cancer samples, especially solid tumors. While these pa-
rameters are valuable for providing information about tumor differenti-
ation, aggressiveness, and risk of recurrence, they are limited in their
ability to predict individual differences in clinical outcomes [389].
Thus, appropriate biomarkers should be identiﬁed and explored as
early markers of the disease, as indicators of the disease state, and as
predictive and prognostic gauges of treatment effectiveness.
VDAC1 is over-expressed inmany cancer types. This is not surprising
in light of its well-established functions in cell metabolism and energy
production, both important systems for high energy-demanding cancer
cells. As presented above, VDAC1 is themain transporter of ATP, as well
as other metabolites and ions through the OMM. VDAC1 mediates cho-
lesterol transport and distribution in the mitochondrial membrane,
with cancer cells exhibiting much higher cholesterol levels than do
healthy cells. Over-expressed VDAC1 presents anchoring sites for
over-expressed HK, allowing direct transport of mitochondrial ATP
for glucose phosphorylation, thereby increasing the glycolytic rate, a
characteristic of cancer cells (i.e., the Warburg effect) (see Section 7).
Finally, over-expressed VDAC1 offers binding sites for Bcl2 and Bcl-xL,
allowing these proteins to mediate their anti-apoptotic activities (see
Section 8.2).
Several studies have demonstrated remarkable differences in the
expression of VDAC between cancer cell lines and tumors and normal
tissues. Similarly, the transcript levels of the three VDAC isoforms
were signiﬁcantly higher in AH130 than in normal liver cells. In addi-
tion, higher VDAC1 levels were associated with sarcomatous alterations
of primary malignancies of the biliary tract [390]. Mass spectrometry
and Western blot analysis of gastric cancer cells identiﬁed altered ex-
pression levels of nine apoptosis-related proteins, including VDAC1
[391]. VDAC1 expression in several cancer cell lines was higher than in
a control ﬁbroblast cell line [163,252]. Non-small cell lung cancer
(NSCLC) cells speciﬁcally exhibited high VDAC1 expression levels. In
this respect, immunoblot analysis of lung cancer tissue revealed that a
C-terminally truncated VDAC1 (VDAC1-ΔC) was present in tumor cells
exposed to hypoxia [392]. This hypoxia-induced form of VDAC1 was
detected in tissues of 50% of 46 patients with lung cancer [392] and
was shown to be associated with resistance to chemotherapy-induced
apoptosis in some cancer cell lines [392].
The over-expression of VDAC1 in a panel of cancer types was clearly
demonstrated using cancer tissue arrays and immunhistochemistry
(Fig. 8A,B). VDAC1 expression levels were found to be substantially
Fig. 8. VDAC1 over-expression in cancer. Immunohistochemical staining of VDAC1 was performed on tissuemicroarray slides obtained from Biomax US. Representative sections of cervix
and lung (A) and thyroid andovary (B) showshigher levels of VDAC1 in cancer tissues (n=20) than innormal tissue (n=5),with thepercent of sections stained at the intensity indicated
by the scale above. The slideswere incubatedwith anti-VDAC1 antibodies diluted in 1%BSA inPBS overnight at 4 °C and thenwith secondary antibodies diluted in 1%BSA in PBS. The slides
were subsequently treated with 3’3-diaminobenzidine tetra-hydrochloride (DAB) and counter-stained with hematoxylin. Negative controls without primary antibody incubation were
also performed. Sections of tissuewere observedunder anOlympusmicroscope and imageswere taken at 200×magniﬁcationwith the same light intensity and exposure time. The images
below show 3-fold magniﬁcation of the section area in the black box. C. Representative immunoblots using anti-VDAC1 antibodies of tissue lysates of healthy (H) and tumor (T) tissues
each derived from the same lung of a lung cancer patient (numbered). The fold change represents the increase in VDAC1 level in the tumor in comparison to the healthy tissue, both from
the same patient. D. Representative immunoblot showing VDAC1 over-expression in peripheral blood mononuclear cells (PBMCs) derived from chronic lymphocytic leukemia (CLL)
patients, as compared to PBMCs from healthy donors, as probed with anti-VDAC1 and anti-β-actin antibodies.
2565V. Shoshan-Barmatz et al. / Biochimica et Biophysica Acta 1848 (2015) 2547–2575higher in different cancer types, relative to the non-cancer counterpart
tissues. Among these were thyroid, lung, cervix, ovary, pancrease,
melanoma, glioblastoma cancers. The over-expression of VDAC1 in
cancer cells was further demonstrated by comparing VDAC1 levels in
lung tissue samples taken from healthy and tumor-containing areas of
the same patient (Fig. 8C). Western blot analysis of peripheral blood
mononuclear cells from chronic lymphocytic leukemia (CLL) patients
showed several-fold increase in VDAC1 expression levels, as compared
to the same cells from healthy donors (Fig. 8D). The results clearly
demonstrated that in all tissue samples collected from eleven patients,
VDAC1 was over-expressed in the tumor tissue at levels up to over
8-fold higher than in healthy tissue.
In addition, in several melanoma and prostate cancer cell lines, a
correlation between levels of VDAC1 expression and induction of Cyto
c release by G3139 was demonstrated [250]. Proteomic analysis of
aging-related proteins in humannormal colon epithelial tissues showed
signiﬁcant up-regulation of nineteen proteins, including VDAC1 and
VDAC2 [393]. It has also been shown that CD45 expression is accompa-
nied by elevated VDAC1 expression in myeloma cells sensitized to a di-
verse set of apoptotic stimuli acting via mitochondrial pathways [394].
In addition, VDAC1 expression was correlated with tumor progression
and sensitivity to chemotherapy [395,396], whereas gene expression
analysis of NSCLC patients revealed VDAC1 expression levels as a pre-
dictor of poor outcome [397]. Finally, proteomic analysis of primary
lung adenocarcinoma tumors showed a direct correlation between
VDAC1 up-regulation and poor prognosis [396]. Thus, VDAC1 expres-
sion levels can be used as a molecular biomarker to forecast cancer
development and treatment efﬁcacy and potentially enable early
diagnosis, as well as provide prognostic and treatment guidance.
In accord with its central role in cell metabolism, enhanced VDAC1
expression is advantageous to cancer cells. However, as VDAC1 is
involved in apoptosis, and, as previously demonstrated, increasedVDAC1 expression leads to apoptotic cell death (see Section 5.1),
augmentation of VDAC1 levels can be turned against cancer cells. In
cancer cells, over-expressed anti-apoptotic proteins (i.e. Bcl2, Bcl-xL
and HK) all interact with VDAC1 to prevent its pro-apoptotic
activity [62,121,184,196,197,290]. However, when association of these
proteins with VDAC is interrupted, such as by VDAC1-based peptides
[62,121,184,196,197,290], over-expressed VDAC1 becomes a pro-
apoptotic agent. Thus, VDAC1 over-expression in cancer functions as
double-edged sword, on the one hand providing many advantages to
the cancer cell yet once its regulation by anti-apoptotic proteins is
disrupted, the high levels of VDAC1 encourage oligomerization of
the protein (see Section 4.4). In this case, VDAC1 displays its pro-
apoptotic activity, leading to cell death.9.2. VDAC1 mutations in tumors
Cancer cells accumulate in response to inherited or acquired genetic
abnormalities [398,399]. To analyze mutations in VDAC1, Gene Expres-
sion Omnibus (GEO) [400] and The Cancer Genome Atlas (TCGA) data
were consulted [401]. The latter database contains information collect-
ed from a large number of cancer patients, including sequencing, gene
expression, and clinical data. Analysis of germline (inherited)mutations
in VDAC1 and ﬁfty neighboring genes in colon carcinoma, rectum
adenocarcinoma, serous cyst adenocarcinoma and kidney renal clear
cell carcinoma patients revealed that VDAC1 showed dramatically de-
creased variations than seen in the other neighboring gene (Golan,
Shoshan-Barmatz and Rubin, unpublished data). Modiﬁed versions of
VDAC have been reported. DNA sequencing of colorectal cancer (CRC)
and gastric cancer (GC) revealed a repeated VDAC1 mutation that
leads to a premature stop codon (c.332delA), resulting in truncated
VDAC1 missing about 60% of the C-terminal end of the protein. This
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of GC or CRC [402].
VDAC1 interacts with over a dozen proteins [3] (see Fig. 6) and thus
can be considered as a hub protein. Hub proteins have previously been
shown to be more evolutionarily conserved than are non-hub proteins
[403]. Considering the multiple functions of VDAC1 in the cell, particu-
larly in cancer, it is not surprising that VDAC1 is highly conserved in can-
cers and at the population genetic level aswell. These results are further
supported by the ﬁnding that VDAC1 SNPs are 8.5 times less likely to
alter an amino acid than are SNPs in sixteen neighboring genes. This
also implies that in the human population, VDAC1 is under selection
against any alteration in the encoded protein sequence. An important
conclusion from these results is that VDAC1 is a highly conserved gene
in the human population and even within tumors at the somatic level.
These ﬁndings thus make VDAC1 as an excellent target for anti-cancer
intervention as its low variability between patients reduces the chances
of a genetically stratiﬁed effect and the possibility that tumors will
develop resistance to VDAC1-based drugs by acquiring mutations in
VDAC1.
10. Unraveling VDAC1-based therapies
Cancer cells do not resemble normal cells in terms of morphology or
metabolic behavior [404]. Accordingly, much effort has been invested
worldwide in developing anti-cancer therapies that can kill cancer
cells without harming normal cells. These therapies target functional
molecules that are differentially expressed in cancer and normal, non-
transformed cells. For this purpose, a myriad of new small molecular
weight synthetic and/or natural inhibitor compounds are being tested
toward achieving selective anti-cancer clinical treatments. Small
molecularweight chemicals fromplants (phytochemicals) often display
multi-targeted anti-cancer activities, including cell cycle arrest, inhibi-
tion of cell growth, proliferation and metastasis, and promotion of
apoptosis and cell death [405].
10.1. Small molecule drugs interacting with VDAC
Several drugs have been shown to interact with VDAC1 in manners
that mediate the pro-apoptotic activities of the protein (Table 1).
These reagents include erastin, an anti-tumor agent selective forFig. 9.VDAC1-based anti-cancer therapy approaches. In exploring the function of VDAC1 oligom
several VDAC1-based strategies for cancer therapies were developed (see Section 10).tumor cells bearing oncogenic RAS [406], able to bind to VDAC2 but
not to N-terminal truncated hVDAC2 [407]. Oblimersen (G3139), an
anti-sense oligonucleotide being studied as a possible treatment for
several types of cancer, including CLL [408], B-cell lymphoma [409],
breast cancer [410] and melanoma [250], directly interacts with VDAC
to reduce its channel activity [250,411]. Avicins, a family of triterpenoid
saponins shown to selectively inhibit the growth of various tumor cells
[412,413], target and close VDAC, thus leading to an overall lowering of
cell energy metabolism, subsequently pushing these cells towards the
apoptotic pathway by permeabilization of the OMM and release of
Cyto c [414,415]. Cisplatin is an anti-cancer drug shown to bind prefer-
entially tomitochondrialmembrane proteins, and of these, preferential-
ly to VDAC [416] to modulate its activity [245]. Endostatin is a broad
spectrum angiogenesis inhibitor demonstrated to promote PTP opening
via VDAC1 [188]. Methyl jasmonate (MJ) is a natural cyclopentanone
lipid belonging to the jasmonate (JA) family of plant oxylipin stress hor-
mones (oxygenated fatty acids) [417]. MJ directly interacts with VDAC1
reconstituted into a planar lipid bilayer, reducing channel conductance
[291]. One of the major ﬁndings concerning MJ was its ability to detach
HK from VDAC1 in a time- and dose-dependent fashion. Dissociation of
HK from VDAC1 leads to a dissociating of glycolytic and mitochondrial
metabolic functions accompanied by cytochrome c release, inhibition
of ATP synthesis, and blockage of oxidative phosphorylation, causing a
drastic reduction of intracellular ATP levels and overall irreversible bio-
energetics damage leading to cell death [291,418]. Thus, abrogation of
the anti-apoptotic activity of the VDAC1–HK complex is an attractive
approach to uncouple glycolytic andmitochondrialmetabolic functions.
It should be noted, however, that MJ can affect multiple targets, causing
cell death in varied manners in different cancer cell types and even
within the same cancer cell population [419].
All these drugs were non-systematically identiﬁed as acting via
VDAC. A more speciﬁc approach involving screening for VDAC-
interacting compounds affecting the pro-apoptotic activity of the pro-
tein is needed to identify novel compounds with selectivity for VDAC1.
10.2. VDAC1-based cancer therapeutic strategies
A second class of drugs is based on VDAC1-based therapeutic
strategies. VDAC1 is over-expressed in highly demanding cancer cells.
Being deeply involved in cellular energy and metabolism by serving aserization in apoptosis and showing that VDAC1 serves as a target of anti-apoptotic proteins,
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anti-cancer therapies that aim for cancer's trademark cell metabolic
and energy reprogramming and unique death evasion strategies. Cancer
therapy strategies aimed at thes aspects of VDAC function include siRNA
altering the normal functioning of cancer cells and leading to growth
arrest, and VDAC1-based peptides that impair energy homeostasis and
minimize the self-defense mechanisms of cancer cells. These can,
moreover, be used to overcome protective and pro-survival actions
taken by cancer cells (Fig. 9).
10.2.1. VDAC1-depletion using RNAi
Considering cancer's trademark of cell metabolic and energy
reprogramming, processes essential for tumor progression, and the
role of VDAC1 as a key regulator of these processes [2,3,5,6,12,55],
disrupting cancer energy and metabolism homeostasis via targeting
VDAC1 offers an attractive anti-cancer therapy. Indeed, the importance
of VDAC1 for cancer cells is further reﬂected in the ﬁnding that silencing
VDAC1 expression reduced cellular ATP levels and cell growth [60].
Furthermore, when HeLa cervical cancer cells stably expressing shRNA
directed against hVDAC1 were injected into nude mice, the develop-
ment of a solid tumor was inhibited [420]. It has also been shown that
VDAC1 silencing potentiated H2O2-induced apoptosis and impaired
mitochondrial Ca2+ loading,while silencing VDAC2 had the opposite ef-
fects [261]. Furthermore, a single siRNA speciﬁc to the human VDAC1
sequence (hVDAC1-siRNA) was shown to silence VDAC1 expression
by over 90% at low nanomolar concentrations and inhibit the growth
of various cancer cell types, both in vitro and in vivo [421]. In a xenograft
lung cancer mouse model, chemically modiﬁed VDAC1–siRNA not only
inhibited tumor growth but also resulted in tumor regression [421]. As
cell treatment with VDAC1–siRNA resulted in a decrease in cell energy
production, with tight correlation between cell growth and cellular
ATP levels being seen [60], the dramatic inhibition of cancer cell growth
and tumor development seen was due to a disabling of the abnormal
metabolic behavior of cancer cells. Thus, considering the high expres-
sion level of VDAC1 in tumors (see Section 10.1) and the speciﬁcity of
VDAC1–siRNA for the inhibition of cancer cell and tumor growth, silenc-
ingVDAC1 expression can be considered as a novel strategic therapeutic
approach to treat cancer, potentially paving theway for amore effective
pipeline of anti-cancer drugs.
10.2.2. VDAC1-based peptides as potential anti-cancer therapy
Defects in the regulation of apoptosis are often associated with dis-
ease and drug resistance [422], with evading apoptosis being a hallmark
of cancer [2,3,5,6,270]. Cancer cells utilize a variety of strategies to limit
or circumvent apoptosis, including quenching of the mitochondrial
apoptotic pathway by over-expression of anti-apoptotic proteins, such
as the Bcl-2 family of proteins and HK, thus preventing the release of
Cyto c from mitochondria (see Section 8) [2,6,174,276]. The anti-
apoptotic activities of HK, Bcl-2, and Bcl-xL involve their interaction
with VDAC1 [62,121,184,196,197,290]. Thus, targeting unique cancer
cell death evasion strategies by activating death pathways andminimiz-
ing self-defense mechanisms of the cancer cells are appropriate
anti-cancer strategies. One such approach is based on engineered
VDAC1-based peptides that interfere with the activity of the pro-
survival proteins, Bcl-2, Bcl-Xl and HK [62,121,184,196,197,290].
Via point mutations, VDAC1 domains and amino acids residues
important for interaction with HK, Bcl-2 and Bcl-xL were identiﬁed
and VDAC1-based peptides targeting these interactions were designed
[62,121,184,196,197,290]. The VDAC1-based cell penetrating peptides
Antp-LP4 and N-Terminal-Antp were constructed to contain the cell-
penetrating Antp (Penetrating) sequence, a 16 residue-long sequence
from the Drosophila antennapedia-homeodomain, fused to a VDAC1-
derived sequence [290,423]. These VDAC1-based peptides effectively
induced cancer cell death in a panel of genetically characterized cancer
cell lines, regardless of cancer type or mutation status with perceived
speciﬁcity toward cancerous cells [290,423]. These peptides werefound to induce cell death with features characteristic of apoptosis,
such as release of Cyto c and morphological changes, including cell
shrinkage, membrane blebbing, phosphatidylserine surface exposure,
nuclear condensation and fragmentation [290,423]. The peptides also
induced detachment of mitochondria-bound HK, thereby disrupting
the overall cellular bioenergetics balance of high energy-demanding
cancer cells [290]. The reported results suggest that thepeptides possess
a triple mode of action, namely energy andmetabolism impairment, in-
terference with the action of anti-apoptotic proteins, and triggering cell
death, thus allowing multiple steps to be activated, leading to impair-
ment of cell energy and metabolism homeostasis and to apoptosis
induction. VDAC1-based peptides thus provide the opportunity for the
development of new anti-cancer therapies, allowing for an overcoming
of the chemo-resistance of cancer cells.
11. Perspectives
Delineating the molecular mechanisms underlying the re-
programmed metabolism in human cancers and their cell survival strat-
egies, togetherwith increasedunderstanding of the difﬁculty in targeting
signal transduction of tumors without signiﬁcant side-effects, are
redirecting cancer research efforts to the development of effective new
cancer therapies. Thus, the emergence of targeted therapies speciﬁcally
targeting critical molecules important for cancer cell survival may
provide promising means of selectively killing these malignant cells.
VDAC1 is one such a target.
The recent studies reviewed here have demonstrated the pivotal
roles of mitochondria and VDAC1 in cancer, encouraging prospects for
the development of effective therapies. Research accumulated over re-
cent years points to VDAC1 as being much more than simple channels
that passively allow the exchange of ions, metabolites and nucleotides
to and from mitochondria. Intensive studies have placed VDAC1 at the
crossroads between mitochondrial metabolite transport and apoptosis
and as an emerging cancer drug target. VDAC1 mediates metabolite
cross-talk between mitochondria and the rest of the cell, and as such
is integral to mitochondrial ATP production. VDAC1 provides the
docking site for mitochondrial-bound HK, a protein that is highly
expressed in cancers, with VDAC1-bound HK facilitating and contribut-
ing to the metabolic phenotype of cancer cells. In this respect, the
up-regulation of HK expression in tumor cells and its binding to
VDAC1 provide both a metabolic beneﬁt and apoptosis-suppressive
capacity that offers the cell a growth advantage and increases its resis-
tance to chemotherapy. VDAC1 is associated with the mitochondrial
pathway of apoptosis, interacting with over-expressed anti-apoptotic
proteins present in cancer and mediating the actions of some
anti-cancer drugs. In addition, VDAC1 mediates cholesterol transport
and distribution in the mitochondrial membrane, with cancer cells
exhibiting several fold higher cholesterol levels than do healthy cells.
VDAC1 also functions in ROS production and transport to the cytosol,
with elevated ROS generation being seen in cancer cells. VDAC1 also
functions in mitochondria-ER Ca2+ signaling during the apoptosis pro-
cess. These functions, together with VDAC1 being over-expressed in
some cancer cells, point to VDAC1 as being a rational target for the de-
velopment of a newgeneration of therapeutics. Likewise, a large body of
data suggests that cancer cells express high levels of the anti-apoptotic
Bcl-2 family of proteins, as well as over-express VDAC1, the binding site
of both HK and Bcl-2. As such, the interaction of VDAC with these anti-
apoptotic proteins also presents a target for anti-cancer drugs.
As a channel, VDAC1 regulatesmetabolismbymediatingmetabolite,
ion and water movement through the OMM under physiological condi-
tions but is also an apoptotic checkpoint in stress and pathological
conditions. This dual function of VDAC1 in both cell metabolism and ap-
optosis, as mediated by the protein alone and regulated by associated
polypeptides, points to VDAC1 as being a rational target for the develop-
ment of a new generation of therapeutics. Such strategies include inter-
ference RNA to down-regulate VDAC1 expression levels [420], VDAC1-
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jesmonate [291]. Altogether, VDAC1-based strategies as anti-cancer
therapies are expected to be highly effective, even in drug-resistance
tumors, and will enhance the sensitivity of cancer cells toward chemo-
therapies, thereby reducing their side effects.
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